Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	B-DNA
early	I-DNA
region	I-DNA
3	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
motifs	I-DNA
.	O

A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
analysis	O
of	O
the	O
viral	B-DNA
control	I-DNA
elements	I-DNA
and	O
the	O
cellular	B-protein
factors	I-protein
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	B-cell_type
has	O
not	O
been	O
reported	O
.	O

The	O
adenovirus	B-protein
early	I-protein
region	I-protein
3	I-protein
(	I-protein
ES	I-protein
)	I-protein
gene	I-protein
products	I-protein
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	B-protein
I	I-protein
MHC	I-protein
antigens	I-protein
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O

To	O
determine	O
whether	O
different	O
cellular	B-protein
factors	I-protein
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	B-cell_type
as	O
compared	O
with	O
HeLa	B-cell_line
cells	I-cell_line
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B-DNA
promoter	I-DNA
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O

These	O
studies	O
detected	O
two	O
novel	B-DNA
domains	I-DNA
referred	O
to	O
as	O
L1	B-DNA
and	O
L2	B-DNA
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O

Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

Transfections	O
of	O
E3	B-DNA
constructs	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	I-DNA
(	O
L2	B-DNA
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	I-DNA
(	O
L1	B-DNA
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	B-cell_line
cells	I-cell_line
and	O
lymphoid	B-cell_type
cells	I-cell_type
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O
reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
when	O
coupled	O
to	O
the	O
L2	B-DNA
mutation	O
.	O

Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	B-DNA
and	O
L2	B-DNA
domains	I-DNA
indicated	O
that	O
the	O
primary	B-DNA
sequence	I-DNA
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	B-DNA
promoter	I-DNA
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	NULL
EMBO	NULL
Journal	NULL
vol.9	NULL
no	NULL
.	NULL

13	NULL
pp.4435-4442	NULL
,	NULL
1990	NULL
Lymphoid	NULL
specific	NULL
gene	NULL
expression	NULL
of	NULL
the	NULL
adenovirus	NULL
early	NULL
region	NULL
3	NULL
promoter	NULL
is	NULL
mediated	NULL
by	NULL
NF-x	NULL
B	NULL
binding	NULL
motifs	NULL
Janice	NULL
L.Williams	NULL
,	NULL
Joseph	NULL
Garcia	NULL
,	NULL
David	NULL
Harrich	NULL
,	NULL
Lori	NULL
Pearson	NULL
,	NULL
Foon	NULL
Wu	NULL
and	NULL
Richard	NULL
Gaynor	NULL
Division	NULL
of	NULL
Hematology	NULL
-Oncology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
UCLA	NULL
School	NULL
of	NULL
Medicine	NULL
and	NULL
Wadsworth	NULL
Veterans	NULL
Hospital	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
90024	NULL
,	NULL
USA	NULL
Communicated	NULL
by	NULL
L.Philipson	NULL
A	NULL
primary	NULL
site	NULL
of	NULL
infection	NULL
by	NULL
human	NULL
adenoviruses	NULL
is	NULL
lymphoid	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
analysis	NULL
of	NULL
the	NULL
viral	NULL
control	NULL
elements	NULL
and	NULL
the	NULL
cellular	NULL
factors	NULL
that	NULL
regulate	NULL
adenoviral	NULL
gene	NULL
expression	NULL
in	NULL
lymphocytes	NULL
has	NULL
not	NULL
been	NULL
reported	NULL
.	NULL

The	NULL
adenovirus	NULL
early	NULL
region	NULL
3	NULL
(	NULL
E3	NULL
)	NULL
gene	NULL
products	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
maintenance	NULL
of	NULL
viral	NULL
persistence	NULL
by	NULL
complexing	NULL
with	NULL
the	NULL
class	NULL
I	NULL
MHC	NULL
antigens	NULL
,	NULL
thus	NULL
preventing	NULL
their	NULL
cell	NULL
surface	NULL
expression	NULL
with	NULL
a	NULL
resultant	NULL
decrease	NULL
in	NULL
host	NULL
immunologic	NULL
destruction	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
different	NULL
cellular	NULL
factors	NULL
were	NULL
involved	NULL
in	NULL
E3	NULL
regulation	NULL
in	NULL
lymphocytes	NULL
as	NULL
compared	NULL
with	NULL
HeLa	NULL
cells	NULL
,	NULL
both	NULL
DNA	NULL
binding	NULL
and	NULL
transfection	NULL
analysis	NULL
with	NULL
the	NULL
E3	NULL
promoter	NULL
in	NULL
both	NULL
cell	NULL
types	NULL
were	NULL
performed	NULL
.	NULL

These	NULL
studies	NULL
detected	NULL
two	NULL
novel	NULL
domains	NULL
referred	NULL
to	NULL
as	NULL
L1	NULL
and	NULL
L2	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
lymphoid	NULL
but	NULL
not	NULL
HeLa	NULL
extracts	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
domains	NULL
possessed	NULL
strong	NULL
homology	NULL
to	NULL
motifs	NULL
previously	NULL
found	NULL
to	NULL
bind	NULL
the	NULL
cellular	NULL
factor	NULL
NF-x	NULL
B.	NULL
Transfections	NULL
of	NULL
E3	NULL
constructs	NULL
linked	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
revealed	NULL
that	NULL
mutagenesis	NULL
of	NULL
the	NULL
distal	NULL
NF-x	NULL
B	NULL
motif	NULL
(	NULL
L2	NULL
)	NULL
had	NULL
minimal	NULL
effects	NULL
on	NULL
promoter	NULL
expression	NULL
in	NULL
Hela	NULL
cells	NULL
,	NULL
but	NULL
resulted	NULL
in	NULL
dramatic	NULL
decreases	NULL
in	NULL
expression	NULL
by	NULL
lymphoid	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
mutagenesis	NULL
of	NULL
proximal	NULL
NF-x	NULL
B	NULL
motif	NULL
(	NULL
L1	NULL
)	NULL
had	NULL
minimal	NULL
effects	NULL
on	NULL
gene	NULL
expression	NULL
in	NULL
both	NULL
HeLa	NULL
cells	NULL
and	NULL
lymphoid	NULL
cells	NULL
but	NULL
resulted	NULL
in	NULL
a	NULL
small	NULL
,	NULL
but	NULL
reproducible	NULL
,	NULL
increase	NULL
in	NULL
gene	NULL
expression	NULL
in	NULL
lymphoid	NULL
cells	NULL
when	NULL
coupled	NULL
to	NULL
the	NULL
L2	NULL
mutation	NULL
.	NULL

Reversing	NULL
the	NULL
position	NULL
and	NULL
subsequent	NULL
mutagenesis	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
indicated	NULL
that	NULL
the	NULL
primary	NULL
sequence	NULL
of	NULL
these	NULL
motifs	NULL
rather	NULL
than	NULL
their	NULL
position	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
was	NULL
critical	NULL
for	NULL
regulating	NULL
gene	NULL
expression	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
E3	NULL
promoter	NULL
contains	NULL
additional	NULL
regulatory	NULL
domains	NULL
which	NULL
function	NULL
to	NULL
modulate	NULL
E3	NULL
gene	NULL
expression	NULL
in	NULL
a	NULL
tissue	NULL
specific	NULL
manner	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
Adenovirus	NULL
early	NULL
promoter/ElA/NF-x	NULL
B	NULL
Introduction	NULL
Human	NULL
adenoviruses	NULL
comprise	NULL
a	NULL
number	NULL
of	NULL
different	NULL
serotypes	NULL
that	NULL
infect	NULL
a	NULL
variety	NULL
of	NULL
human	NULL
cell	NULL
lines	NULL
.	NULL

A	NULL
natural	NULL
host	NULL
for	NULL
these	NULL
viruses	NULL
in	NULL
vivo	NULL
is	NULL
lymphoid	NULL
cells	NULL
(	NULL
Horvath	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Lavery	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Horvath	NULL
and	NULL
Weber	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

Infection	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
usually	NULL
leads	NULL
to	NULL
a	NULL
low	NULL
level	NULL
persistent	NULL
infection	NULL
rather	NULL
than	NULL
a	NULL
lytic	NULL
infection	NULL
as	NULL
found	NULL
in	NULL
tissue	NULL
culture	NULL
with	NULL
HeLa	NULL
cells	NULL
©	NULL
Oxford	NULL
University	NULL
Press	NULL
(	NULL
Horvath	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Horvath	NULL
and	NULL
Weber	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

However	NULL
,	NULL
studies	NULL
of	NULL
adenoviral	NULL
gene	NULL
expression	NULL
and	NULL
growth	NULL
patterns	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
T	NULL
and	NULL
B	NULL
lymphoid	NULL
cell	NULL
lines	NULL
indicated	NULL
characteristic	NULL
patterns	NULL
of	NULL
gene	NULL
expression	NULL
which	NULL
varied	NULL
depending	NULL
on	NULL
the	NULL
individual	NULL
cell	NULL
lines	NULL
(	NULL
Lavery	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
growth	NULL
in	NULL
most	NULL
lymphoid	NULL
cell	NULL
lines	NULL
were	NULL
prolonged	NULL
compared	NULL
with	NULL
expression	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
Lavery	NULL
et	NULL
al	NULL
.	NULL

1987	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
cell-type	NULL
specific	NULL
factors	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
adenovirus	NULL
early	NULL
promoters	NULL
.	NULL

A	NULL
variety	NULL
of	NULL
cellular	NULL
transcription	NULL
factors	NULL
have	NULL
been	NULL
identified	NULL
which	NULL
modulate	NULL
tissue	NULL
specific	NULL
expression	NULL
in	NULL
lymphocytes	NULL
.	NULL

One	NULL
of	NULL
the	NULL
best	NULL
studied	NULL
of	NULL
these	NULL
factors	NULL
is	NULL
NF-x	NULL
B	NULL
(	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986a	NULL
,	NULL
b	NULL
;	NULL
Atchison	NULL
and	NULL
Perry	NULL
,	NULL
1987	NULL
;	NULL
Kawakami	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Lenardo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Nelson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Pierce	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Schreck	NULL
and	NULL
Baeuerle	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

This	NULL
protein	NULL
was	NULL
initially	NULL
found	NULL
to	NULL
be	NULL
produced	NULL
in	NULL
high	NULL
levels	NULL
in	NULL
mature	NULL
B	NULL
lymphocytes	NULL
,	NULL
but	NULL
not	NULL
in	NULL
immature	NULL
B	NULL
cells	NULL
(	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

However	NULL
,	NULL
high	NULL
levels	NULL
of	NULL
this	NULL
protein	NULL
have	NULL
also	NULL
been	NULL
found	NULL
to	NULL
be	NULL
present	NULL
in	NULL
mature	NULL
T	NULL
lymphocytes	NULL
(	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

This	NULL
protein	NULL
was	NULL
subsequently	NULL
found	NULL
to	NULL
be	NULL
present	NULL
in	NULL
non-lymphoid	NULL
cell	NULL
lines	NULL
where	NULL
it	NULL
is	NULL
presumably	NULL
complexed	NULL
in	NULL
the	NULL
cytoplasm	NULL
with	NULL
a	NULL
protein	NULL
known	NULL
as	NULL
IkB	NULL
(	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1988a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

Upon	NULL
treatment	NULL
with	NULL
phorbol	NULL
esters	NULL
,	NULL
NF-x	NULL
B	NULL
is	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
it	NULL
is	NULL
capable	NULL
of	NULL
inducing	NULL
gene	NULL
expression	NULL
(	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986b	NULL
;	NULL
Baecuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1988a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

Nf-x	NULL
B	NULL
binds	NULL
to	NULL
an	NULL
11	NULL
bp	NULL
sequence	NULL
GGGGACTTTCC	NULL
which	NULL
is	NULL
found	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cellular	NULL
and	NULL
viral	NULL
regulatory	NULL
regions	NULL
(	NULL
Boshart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986a	NULL
,	NULL
b	NULL
;	NULL
Davidson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Ondek	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Schirm	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Nabel	NULL
and	NULL
Baltimore	NULL
,	NULL
1987	NULL
;	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988a	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
variety	NULL
of	NULL
other	NULL
nuclear	NULL
proteins	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
bind	NULL
to	NULL
this	NULL
motif	NULL
(	NULL
Yano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Baldwin	NULL
and	NULL
Sharp	NULL
,	NULL
1987	NULL
,	NULL
1988	NULL
;	NULL
Clark	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

Adenovirus	NULL
early	NULL
promoter	NULL
gene	NULL
expression	NULL
has	NULL
been	NULL
extensively	NULL
studied	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
reviewed	NULL
in	NULL
Berk	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

These	NULL
promoters	NULL
are	NULL
strongly	NULL
induced	NULL
by	NULL
the	NULL
ElA	NULL
protein	NULL
(	NULL
Berk	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Jones	NULL
and	NULL
Shenk	NULL
,	NULL
1979	NULL
)	NULL
.	NULL

ElA	NULL
is	NULL
capable	NULL
of	NULL
inducing	NULL
transcription	NULL
through	NULL
a	NULL
number	NULL
of	NULL
different	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
in	NULL
these	NULL
promoters	NULL
.	NULL

One	NULL
of	NULL
the	NULL
best	NULL
studied	NULL
of	NULL
the	NULL
early	NULL
promoters	NULL
is	NULL
the	NULL
early	NULL
region	NULL
3	NULL
(	NULL
E3	NULL
)	NULL
promoter	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Hurst	NULL
and	NULL
Jones	NULL
,	NULL
1987	NULL
;	NULL
Kornuc	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Four	NULL
regions	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
have	NULL
been	NULL
identified	NULL
which	NULL
serve	NULL
as	NULL
binding	NULL
sites	NULL
for	NULL
cellular	NULL
factors	NULL
,	NULL
NF1	NULL
,	NULL
AP1	NULL
,	NULL
CREB/ATF	NULL
and	NULL
TF	NULL
IID	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Hurst	NULL
and	NULL
Jones	NULL
,	NULL
1987	NULL
;	NULL
Komuc	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Mutagenesis	NULL
of	NULL
these	NULL
binding	NULL
sites	NULL
indicated	NULL
that	NULL
both	NULL
the	NULL
API	NULL
and	NULL
CREB/ATF	NULL
sites	NULL
were	NULL
critical	NULL
for	NULL
both	NULL
basal	NULL
and	NULL
E1A/E1B	NULL
induced	NULL
gene	NULL
expression	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Kornuc	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
E3	NULL
promoter	NULL
regulates	NULL
the	NULL
gene	NULL
expression	NULL
of	NULL
a	NULL
19	NULL
kd	NULL
glycoprotein	NULL
which	NULL
functions	NULL
in	NULL
inhibiting	NULL
the	NULL
expression	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
antigens	NULL
(	NULL
Kvist	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
;	NULL
Persson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
,	NULL
1980	NULL
;	NULL
Signas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
;	NULL
Kampe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
;	NULL
Andersson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Burgert	NULL
and	NULL
4435	NULL
J.L	NULL
.	NULL

Williams	NULL
et	NULL
al	NULL
.	NULL

Kvist	NULL
,	NULL
1985	NULL
;	NULL
Paabo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Burgert	NULL
et	NULL
al	NULL
.	NULL

1987	NULL
)	NULL
.	NULL

The	NULL
19	NULL
kd	NULL
gene	NULL
product	NULL
complexes	NULL
with	NULL
class	NULL
I	NULL
antigens	NULL
preventing	NULL
their	NULL
expression	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
(	NULL
Kvist	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
;	NULL
Signas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
;	NULL
Kampe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
;	NULL
Burgert	NULL
and	NULL
Kvist	NULL
,	NULL
1985	NULL
;	NULL
Burgert	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
E3	NULL
is	NULL
important	NULL
in	NULL
decreasing	NULL
host	NULL
immunologic	NULL
response	NULL
to	NULL
viral	NULL
antigens	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
pattern	NULL
of	NULL
regulation	NULL
of	NULL
the	NULL
adenovirus	NULL
early	NULL
region	NULL
3	NULL
promoter	NULL
was	NULL
the	NULL
same	NULL
in	NULL
lymphoid	NULL
and	NULL
HeLa	NULL
cells	NULL
,	NULL
DNase	NULL
I	NULL
footprinting	NULL
and	NULL
gel	NULL
retardation	NULL
with	NULL
these	NULL
cellular	NULL
extracts	NULL
was	NULL
performed	NULL
.	NULL

Two	NULL
binding	NULL
sites	NULL
for	NULL
Nf-x	NULL
B	NULL
known	NULL
as	NULL
L1	NULL
and	NULL
L2	NULL
,	NULL
which	NULL
differ	NULL
in	NULL
both	NULL
their	NULL
binding	NULL
affinity	NULL
and	NULL
their	NULL
effects	NULL
on	NULL
E3	NULL
gene	NULL
expression	NULL
,	NULL
were	NULL
identified	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Oligonucleotide-directed	NULL
mutagenesis	NULL
of	NULL
these	NULL
sites	NULL
was	NULL
performed	NULL
and	NULL
the	NULL
mutant	NULL
promoters	NULL
were	NULL
fused	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
for	NULL
analysis	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
both	NULL
lymphoid	NULL
and	NULL
HeLa	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
the	NULL
E1A/E1B	NULL
proteins	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
position	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
in	NULL
regulating	NULL
E3	NULL
gene	NULL
expression	NULL
was	NULL
also	NULL
determined	NULL
.	NULL

The	NULL
results	NULL
of	NULL
these	NULL
studies	NULL
have	NULL
defined	NULL
novel	NULL
E3	NULL
promoter	NULL
regulatory	NULL
domains	NULL
required	NULL
for	NULL
expression	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Results	NULL
Lymphoid	NULL
specific	NULL
binding	NULL
domains	NULL
in	NULL
the	NULL
adenovirus	NULL
E3	NULL
promoters	NULL
Partially	NULL
purified	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
either	NULL
HeLa	NULL
cells	NULL
or	NULL
a	NULL
variety	NULL
of	NULL
different	NULL
lymphoid	NULL
cells	NULL
including	NULL
the	NULL
T	NULL
cell	NULL
lines	NULL
,	NULL
Jurkat	NULL
(	NULL
Gillis	NULL
and	NULL
Watson	NULL
,	NULL
1980	NULL
)	NULL
,	NULL
HUT	NULL
78	NULL
(	NULL
Gootenberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
and	NULL
a	NULL
closely	NULL
related	NULL
derivative	NULL
of	NULL
this	NULL
line	NULL
,	NULL
H9	NULL
(	NULL
Popovic	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
,	NULL
or	NULL
the	NULL
B	NULL
cell	NULL
line	NULL
Raji	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
revealed	NULL
six	NULL
binding	NULL
sites	NULL
with	NULL
lymphoid	NULL
extract	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

Four	NULL
of	NULL
these	NULL
binding	NULL
domains	NULL
,	NULL
including	NULL
the	NULL
TATA	NULL
,	NULL
CREB/ATF	NULL
and	NULL
NFI	NULL
sites	NULL
,	NULL
were	NULL
previously	NULL
identified	NULL
using	NULL
HeLa	NULL
extract	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Hurst	NULL
and	NULL
Jones	NULL
,	NULL
1987	NULL
;	NULL
Kornuc	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Two	NULL
previously	NULL
unreported	NULL
binding	NULL
domains	NULL
designated	NULL
as	NULL
L1	NULL
and	NULL
L2	NULL
,	NULL
were	NULL
noted	NULL
in	NULL
DNase	NULL
I	NULL
footprinting	NULL
with	NULL
all	NULL
of	NULL
the	NULL
above	NULL
mentioned	NULL
lymphoid	NULL
extracts	NULL
.	NULL

This	NULL
is	NULL
illustrated	NULL
in	NULL
Figure	NULL
1	NULL
with	NULL
the	NULL
following	NULL
cellular	NULL
extracts	NULL
:	NULL
A	NULL
(	NULL
H9	NULL
)	NULL
,	NULL
C	NULL
(	NULL
Raji	NULL
)	NULL
and	NULL
D	NULL
(	NULL
HUT	NULL
78	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
extending	NULL
from	NULL
-237	NULL
to	NULL
+1	NULL
is	NULL
shown	NULL
and	NULL
the	NULL
position	NULL
of	NULL
the	NULL
binding	NULL
motifs	NULL
are	NULL
indicated	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Examination	NULL
of	NULL
these	NULL
sequences	NULL
indicate	NULL
that	NULL
one	NULL
of	NULL
these	NULL
lymphoid	NULL
specific	NULL
sites	NULL
between	NULL
-137	NULL
and	NULL
-155	NULL
known	NULL
as	NULL
L2	NULL
contains	NULL
complete	NULL
homology	NULL
to	NULL
an	NULL
NF-x	NULL
B	NULL
binding	NULL
site	NULL
found	NULL
in	NULL
the	NULL
immunoglobulin	NULL
kappa	NULL
(	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986a	NULL
,	NULL
b	NULL
)	NULL
,	NULL
HIV	NULL
(	NULL
Nabel	NULL
and	NULL
Baltimore	NULL
,	NULL
1987	NULL
;	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988a	NULL
;	NULL
Gaynor	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
,	NULL
SV	NULL
40	NULL
(	NULL
Davidson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Nomiyama	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Ondek	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Schirm	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Macchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
and	NULL
CMV	NULL
(	NULL
Boshart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
enhancers	NULL
.	NULL

The	NULL
other	NULL
site	NULL
known	NULL
as	NULL
L1	NULL
between	NULL
-113	NULL
and	NULL
-	NULL
134	NULL
contains	NULL
a	NULL
seven	NULL
out	NULL
of	NULL
ten	NULL
nucleotide	NULL
match	NULL
with	NULL
the	NULL
L2	NULL
binding	NULL
motif	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

Variations	NULL
in	NULL
NF-x	NULL
B	NULL
binding	NULL
motifs	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cellular	NULL
and	NULL
viral	NULL
promoter	NULL
elements	NULL
and	NULL
their	NULL
alignment	NULL
with	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
are	NULL
illustrated	NULL
in	NULL
Figure	NULL
2B	NULL
(	NULL
Boshart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Davidson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Nabel	NULL
and	NULL
Baltimore	NULL
,	NULL
1987	NULL
;	NULL
Schirm	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Ballard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Bohnlein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Cross	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Schreck	NULL
and	NULL
Baeuerle	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

Oligonucleotide	NULL
mutagenesis	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
binding	NULL
4436	NULL
domains	NULL
,	NULL
both	NULL
individually	NULL
and	NULL
together	NULL
,	NULL
was	NULL
performed	NULL
.	NULL

The	NULL
nucleotides	NULL
changes	NULL
in	NULL
each	NULL
of	NULL
these	NULL
constructs	NULL
are	NULL
indicated	NULL
in	NULL
Figure	NULL
2A	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
constructs	NULL
was	NULL
used	NULL
in	NULL
DNase	NULL
I	NULL
footprinting	NULL
with	NULL
either	NULL
lymphoid	NULL
(	NULL
Figure	NULL
1A	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
or	NULL
HeLa	NULL
extract	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
either	NULL
the	NULL
L1	NULL
,	NULL
L2	NULL
or	NULL
L1/L2	NULL
binding	NULL
domains	NULL
eliminated	NULL
protection	NULL
of	NULL
their	NULL
respective	NULL
domains	NULL
with	NULL
lymphoid	NULL
extract	NULL
,	NULL
but	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
protection	NULL
of	NULL
the	NULL
remaining	NULL
E3	NULL
binding	NULL
domains	NULL
observed	NULL
with	NULL
either	NULL
lymphoid	NULL
or	NULL
HeLa	NULL
extract	NULL
(	NULL
Figure	NULL
1A	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
two	NULL
domains	NULL
responsible	NULL
for	NULL
lymphoid	NULL
specific	NULL
binding	NULL
domains	NULL
exist	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
with	NULL
extracts	NULL
prepared	NULL
from	NULL
either	NULL
T	NULL
or	NULL
B	NULL
lymphocytes	NULL
.	NULL

NF-x	NULL
B	NULL
binds	NULL
to	NULL
both	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
with	NULL
different	NULL
affinities	NULL
The	NULL
presence	NULL
of	NULL
two	NULL
potential	NULL
NF-x	NULL
B	NULL
motifs	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
was	NULL
further	NULL
investigated	NULL
by	NULL
gel	NULL
retardation	NULL
analysis	NULL
.	NULL

Double	NULL
stranded	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
each	NULL
of	NULL
these	NULL
lymphoid	NULL
specific	NULL
binding	NULL
domains	NULL
were	NULL
end-labeled	NULL
to	NULL
the	NULL
same	NULL
relative	NULL
specific	NULL
activity	NULL
with	NULL
yATP	NULL
and	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
with	NULL
either	NULL
lymphoid	NULL
or	NULL
HeLa	NULL
extract	NULL
.	NULL

Oligonucleotides	NULL
corresponding	NULL
to	NULL
either	NULL
the	NULL
L1	NULL
or	NULL
L2	NULL
binding	NULL
domain	NULL
resulted	NULL
in	NULL
two	NULL
gel	NULL
retarded	NULL
species	NULL
when	NULL
using	NULL
lymphoid	NULL
extracts	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Competition	NULL
analysis	NULL
indicated	NULL
that	NULL
the	NULL
slower	NULL
mobility	NULL
complex	NULL
was	NULL
specific	NULL
to	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
binding	NULL
sites	NULL
while	NULL
the	NULL
faster	NULL
mobility	NULL
complex	NULL
was	NULL
non-specific	NULL
.	NULL

Similar	NULL
non-specific	NULL
products	NULL
using	NULL
NF-x	NULL
B	NULL
fragments	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
have	NULL
previously	NULL
been	NULL
reported	NULL
(	NULL
Macchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
results	NULL
observed	NULL
with	NULL
lymphoid	NULL
extract	NULL
,	NULL
gel	NULL
retardation	NULL
analyses	NULL
of	NULL
these	NULL
probes	NULL
with	NULL
HeLa	NULL
extract	NULL
resulted	NULL
in	NULL
only	NULL
the	NULL
faster	NULL
mobility	NULL
non-specific	NULL
species	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
tissue	NULL
specific	NULL
proteins	NULL
of	NULL
similar	NULL
mobility	NULL
bound	NULL
to	NULL
these	NULL
motifs	NULL
with	NULL
lymphoid	NULL
but	NULL
not	NULL
HeLa	NULL
extracts	NULL
.	NULL

Competition	NULL
studies	NULL
using	NULL
unlabeled	NULL
double	NULL
stranded	NULL
oligonucleotides	NULL
complementary	NULL
to	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
binding	NULL
sites	NULL
were	NULL
performed	NULL
to	NULL
determine	NULL
if	NULL
the	NULL
lymphoid	NULL
specific	NULL
binding	NULL
protein	NULL
had	NULL
similar	NULL
affinity	NULL
to	NULL
both	NULL
sites	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
double	NULL
stranded	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
E3	NULL
NFI	NULL
binding	NULL
site	NULL
were	NULL
also	NULL
used	NULL
as	NULL
a	NULL
competitor	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
competition	NULL
with	NULL
either	NULL
a	NULL
35-fold	NULL
excess	NULL
of	NULL
cold	NULL
L1	NULL
or	NULL
L2	NULL
oligonucleotides	NULL
was	NULL
capable	NULL
of	NULL
markedly	NULL
competing	NULL
the	NULL
slower	NULL
mobility	NULL
L1	NULL
gel	NULL
retarded	NULL
species	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Competition	NULL
with	NULL
a	NULL
35-fold	NULL
excess	NULL
of	NULL
NFI	NULL
oligonucleotides	NULL
did	NULL
not	NULL
result	NULL
in	NULL
significant	NULL
competition	NULL
of	NULL
the	NULL
slower	NULL
mobility	NULL
complex	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
competition	NULL
with	NULL
either	NULL
a	NULL
35-fold	NULL
excess	NULL
of	NULL
L1	NULL
or	NULL
L2	NULL
oligonucleotides	NULL
was	NULL
capable	NULL
of	NULL
markedly	NULL
competing	NULL
the	NULL
L2	NULL
gel	NULL
retarded	NULL
species	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
.	NULL

NFI	NULL
oligonucleotides	NULL
did	NULL
not	NULL
result	NULL
in	NULL
significant	NULL
competition	NULL
of	NULL
the	NULL
L2	NULL
specific	NULL
complex	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
sites	NULL
bound	NULL
the	NULL
same	NULL
lymphoid	NULL
specific	NULL
protein	NULL
.	NULL

Since	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
gel	NULL
retarded	NULL
species	NULL
was	NULL
stronger	NULL
with	NULL
the	NULL
L2	NULL
oligonucleotides	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
L1	NULL
oligonucleotides	NULL
,	NULL
competition	NULL
of	NULL
the	NULL
L2	NULL
gel	NULL
retarded	NULL
species	NULL
was	NULL
performed	NULL
with	NULL
carefully	NULL
quantitated	NULL
amounts	NULL
of	NULL
either	NULL
unlabeled	NULL
L1	NULL
,	NULL
L2	NULL
or	NULL
NFI	NULL
oligonucleotides	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
3B	NULL
,	NULL
the	NULL
L2	NULL
gel	NULL
retarded	NULL
species	NULL
was	NULL
completely	NULL
competed	NULL
between	NULL
a	NULL
15	NULL
to	NULL
30-fold	NULL
molar	NULL
excess	NULL
of	NULL
L2	NULL
oligonucleotides	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
whereas	NULL
these	NULL
same	NULL
concentrations	NULL
of	NULL
L1	NULL
oligonucleotides	NULL
did	NULL
not	NULL
result	NULL
in	NULL
complete	NULL
Adenovirus	NULL
early	NULL
region	NULL
3	NULL
promoter	NULL
Do	NULL
@	NULL
@	NULL
@	NULL
«	NULL
DGG	NULL
#	NULL
#	NULL
¥	NULL
@	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
with	NULL
HeLa	NULL
and	NULL
lymphoid	NULL
extracts	NULL
.	NULL

The	NULL
coding	NULL
strand	NULL
of	NULL
either	NULL
the	NULL
wild-type	NULL
E3	NULL
promoter	NULL
,	NULL
or	NULL
mutations	NULL
of	NULL
lymphoid	NULL
domain	NULL
1	NULL
(	NULL
L1	NULL
)	NULL
,	NULL
lymphoid	NULL
domain	NULL
2	NULL
(	NULL
L2	NULL
)	NULL
,	NULL
or	NULL
both	NULL
of	NULL
these	NULL
domains	NULL
(	NULL
LI/L2	NULL
)	NULL
were	NULL
used	NULL
in	NULL
DNase	NULL
I	NULL
footprinting	NULL
with	NULL
H9	NULL
(	NULL
A	NULL
)	NULL
,	NULL
HeLa	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
Raji	NULL
(	NULL
C	NULL
)	NULL
or	NULL
HUT	NULL
78	NULL
(	NULL
D	NULL
)	NULL
extract	NULL
.	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
Lanes	NULL
0	NULL
,	NULL
3	NULL
,	NULL
6	NULL
and	NULL
9	NULL
contain	NULL
no	NULL
extract	NULL
;	NULL
lanes	NULL
1	NULL
,	NULL
4	NULL
,	NULL
7	NULL
and	NULL
10	NULL
contain	NULL
50	NULL
ug	NULL
of	NULL
extract	NULL
;	NULL
and	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
8	NULL
and	NULL
11	NULL
contain	NULL
100	NULL
ug	NULL
of	NULL
extract	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Lane	NULL
0	NULL
contains	NULL
no	NULL
extract	NULL
;	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
and	NULL
7	NULL
contain	NULL
50	NULL
ug	NULL
of	NULL
extract	NULL
;	NULL
and	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
and	NULL
8	NULL
contain	NULL
100	NULL
ag	NULL
of	NULL
extract	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Lane	NULL
0	NULL
contains	NULL
no	NULL
extract	NULL
;	NULL
lane	NULL
1	NULL
contains	NULL
50	NULL
ug	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
100	NULL
ug	NULL
;	NULL
and	NULL
lane	NULL
3	NULL
,	NULL
150	NULL
ug	NULL
of	NULL
extract	NULL
respectively	NULL
.	NULL

Maxam-Gilbert	NULL
sequencing	NULL
of	NULL
the	NULL
E3	NULL
wild-type	NULL
promoter	NULL
shown	NULL
in	NULL
(	NULL
B	NULL
)	NULL
was	NULL
adjacent	NULL
to	NULL
panel	NULL
(	NULL
A	NULL
)	NULL
in	NULL
the	NULL
original	NULL
gel	NULL
for	NULL
use	NULL
in	NULL
demarcating	NULL
binding	NULL
domains	NULL
.	NULL

A	NULL
GaaTTCTCCTCGAACAGGCGGCTATTACCACCACACCTCGTAATAACCTTAATCCCCG	NULL
-	NULL
237	NULL
CTCGAG	NULL
C_	NULL
GAG	NULL
TaAGTTGGCCCGCTGCCCTGGTGTACCAGGAaAAGTCCCGCTCCGAGCACTGTGGTACTTCCCAGAGAGGCCCAGGCC	NULL
-	NULL
1	NULL
79	NULL
Iv	NULL
-	NULL
1	NULL
5	NULL
6	NULL
Lymphoid	NULL
II	NULL
-	NULL
137	NULL
-	NULL
134	NULL
Lymphoid	NULL
I	NULL
-	NULL
113	NULL
GAAGTTCAGATGACTAACTCAGGGGCGCAGCTTGCdGGCGGCTTTCGTCACAGGGTGCGGTCGCCC	NULL
-	NULL
1	NULL
0	NULL
3	NULL
HI	NULL
-	NULL
8	NULL
3	NULL
-	NULL
6	NULL
7	NULL
IL	NULL
-	NULL
4	NULL
7	NULL
GGGCAGGGTATAACTCACCTGAAAATCAGAGGGCGAGG	NULL
-	NULL
3	NULL
7	NULL
I	NULL
-	NULL
1	NULL
6	NULL
+1	NULL
B	NULL
NF-kappa	NULL
B	NULL
binding	NULL
domains	NULL
Lymphoid	NULL
1	NULL
G	NULL
G	NULL
G	NULL
A	NULL
A	NULL
G	NULL
T	NULL
A	NULL
C	NULL
Lymphoid	NULL
2	NULL
G	NULL
G	NULL
G	NULL
a	NULL
C	NULL
T	NULL
T	NULL
C	NULL
Kappa	NULL
enhancer	NULL
,	NULL
G	NULL
G	NULL
G	NULL
A	NULL
C	NULL
T	NULL
T	NULL
C	NULL
C	NULL
SV	NULL
40	NULL
,	NULL
HIV	NULL
,	NULL
CMV	NULL
IL-2R	NULL
G	NULL
G6	NULL
G	NULL
a	NULL
a	NULL
T	NULL
C	NULL
T	NULL
C	NULL
C	NULL
-IFN	NULL
G	NULL
G	NULL
G	NULL
a	NULL
A	NULL
A	NULL
T	NULL
T	NULL
C	NULL
C	NULL
IL-2	NULL
G	NULL
G	NULL
G	NULL
a	NULL
T	NULL
T	NULL
T	NULL
C	NULL
aA	NULL
C	NULL
GM-CSF-1	NULL
G	NULL
G	NULL
G	NULL
a	NULL
aA	NULL
C	NULL
T	NULL
a	NULL
C	NULL
C	NULL
GM-CSF-2	NULL
T	NULL
G	NULL
G	NULL
a	NULL
a	NULL
T	NULL
C	NULL
T	NULL
C	NULL
C	NULL
Consensus	NULL
G	NULL
G	NULL
G	NULL
A	NULL
N	NULL
N	NULL
Y	NULL
Y	NULL
C	NULL
C	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Schematic	NULL
diagram	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
extending	NULL
from	NULL
-237	NULL
to	NULL
+1	NULL
is	NULL
indicated	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
binding	NULL
domains	NULL
protected	NULL
with	NULL
both	NULL
lymphoid	NULL
and	NULL
HeLa	NULL
extracts	NULL
are	NULL
indicated	NULL
(	NULL
I-IV	NULL
)	NULL
as	NULL
are	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
two	NULL
domains	NULL
protected	NULL
with	NULL
only	NULL
lymphoid	NULL
extracts	NULL
(	NULL
Lymphoid	NULL
I	NULL
and	NULL
II	NULL
)	NULL
.	NULL

The	NULL
base	NULL
pairs	NULL
altered	NULL
by	NULL
oligonucleotide-directed	NULL
mutagenesis	NULL
are	NULL
also	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
L1	NULL
and	NULL
the	NULL
L2	NULL
binding	NULL
domains	NULL
are	NULL
aligned	NULL
with	NULL
NF-x	NULL
B	NULL
binding	NULL
motifs	NULL
in	NULL
regulatory	NULL
elements	NULL
in	NULL
the	NULL
immunoglobulin	NULL
x	NULL
,	NULL
SV40	NULL
,	NULL
HIV	NULL
,	NULL
CMV	NULL
,	NULL
IL-2	NULL
receptor	NULL
,	NULL
B-interferon	NULL
,	NULL
IL-2	NULL
and	NULL
GM-CSF	NULL
enhancers	NULL
.	NULL

4437	NULL
J.L.Williams	NULL
et	NULL
al	NULL
.	NULL

A	NULL
B	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Gel	NULL
retardation	NULL
with	NULL
HeLa	NULL
and	NULL
lymphoid	NULL
extract	NULL
.	NULL

(	NULL
A	NULL
)	NULL
L1	NULL
(	NULL
lanes	NULL
1-4	NULL
and	NULL
11	NULL
)	NULL
and	NULL
L2	NULL
(	NULL
lanes	NULL
6-10	NULL
and	NULL
12	NULL
)	NULL
oligonucleotides	NULL
were	NULL
end-labeled	NULL
with	NULL
yATP	NULL
and	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
with	NULL
3	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
prepared	NULL
from	NULL
either	NULL
HUT	NULL
78	NULL
(	NULL
lanes	NULL
1-10	NULL
)	NULL
or	NULL
HeLa	NULL
(	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
cells	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
6	NULL
contain	NULL
probe	NULL
alone	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
contain	NULL
extract	NULL
with	NULL
no	NULL
competition	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
contain	NULL
a	NULL
35-fold	NULL
molar	NULL
excess	NULL
of	NULL
L1	NULL
oligonucleotides	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
contain	NULL
a	NULL
35-fold	NULL
molar	NULL
excess	NULL
of	NULL
L2	NULL
oligonucleotides	NULL
,	NULL
and	NULL
lanes	NULL
5	NULL
and	NULL
I0	NULL
contain	NULL
a	NULL
35-fold	NULL
molar	NULL
excess	NULL
of	NULL
NFI	NULL
oligonucleotides	NULL
.	NULL

Lanes	NULL
11	NULL
and	NULL
12	NULL
contain	NULL
either	NULL
L1	NULL
or	NULL
L2	NULL
oligonucleotides	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
3	NULL
ug	NULL
of	NULL
HeLa	NULL
extract	NULL
.	NULL

(	NULL
B	NULL
)	NULL
L2	NULL
oligonucleotides	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
extract	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
HUT	NULL
78	NULL
extract	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
2	NULL
,	NULL
6	NULL
,	NULL
15	NULL
or	NULL
30-fold	NULL
excess	NULL
of	NULL
cold	NULL
L1	NULL
oligonucleotides	NULL
(	NULL
lanes	NULL
3-6	NULL
)	NULL
or	NULL
similar	NULL
concentrations	NULL
of	NULL
L2	NULL
(	NULL
lanes	NULL
7-10	NULL
)	NULL
or	NULL
NFI	NULL
oligonucleotides	NULL
(	NULL
lanes	NULL
11-14	NULL
)	NULL
.	NULL

competition	NULL
of	NULL
this	NULL
species	NULL
.	NULL

Densitometry	NULL
of	NULL
these	NULL
gel	NULL
retardations	NULL
at	NULL
either	NULL
a	NULL
6	NULL
or	NULL
15-fold	NULL
molar	NULL
excess	NULL
of	NULL
competitor	NULL
indicated	NULL
that	NULL
the	NULL
L2	NULL
oligonucleotides	NULL
were	NULL
a	NULL
3	NULL
to	NULL
4-fold	NULL
better	NULL
competitor	NULL
than	NULL
the	NULL
L1	NULL
oligonucleotides	NULL
(	NULL
Figure	NULL
3B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
as	NULL
compared	NULL
with	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
.	NULL

NFI	NULL
oligonucleotides	NULL
did	NULL
not	NULL
result	NULL
in	NULL
significant	NULL
competition	NULL
at	NULL
these	NULL
same	NULL
concentrations	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
L2	NULL
region	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
consensus	NULL
NF-x	NULL
B	NULL
binding	NULL
sequence	NULL
,	NULL
has	NULL
a	NULL
higher	NULL
binding	NULL
affinity	NULL
for	NULL
the	NULL
lymphoid	NULL
specific	NULL
factor	NULL
than	NULL
the	NULL
divergent	NULL
L1	NULL
region	NULL
.	NULL

L2	NULL
is	NULL
required	NULL
for	NULL
efficient	NULL
E3	NULL
gene	NULL
expression	NULL
in	NULL
lymphocytes	NULL
Mutations	NULL
in	NULL
either	NULL
domains	NULL
L1	NULL
,	NULL
L2	NULL
or	NULL
L1/L2	NULL
were	NULL
substituted	NULL
into	NULL
the	NULL
context	NULL
of	NULL
the	NULL
wild-type	NULL
E3	NULL
promoter	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
constructs	NULL
or	NULL
the	NULL
wild-type	NULL
E3	NULL
CAT	NULL
construct	NULL
were	NULL
transfected	NULL
into	NULL
either	NULL
the	NULL
T	NULL
lymphocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
HUT	NULL
78	NULL
,	NULL
or	NULL
HeLa	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
wild-type	NULL
adenovirus	NULL
or	NULL
dl	NULL
434	NULL
,	NULL
an	NULL
EIA/E1B	NULL
deletion	NULL
mutant	NULL
.	NULL

Transfections	NULL
were	NULL
harvested	NULL
at	NULL
between	NULL
30-36	NULL
h	NULL
post	NULL
4438	NULL
&	NULL
#	NULL
©	NULL
®	NULL
|	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

E3	NULL
gene	NULL
expression	NULL
in	NULL
HeLa	NULL
and	NULL
HUT	NULL
78	NULL
cells	NULL
.	NULL

The	NULL
E3	NULL
promoter	NULL
containing	NULL
either	NULL
wild-type	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
or	NULL
containing	NULL
mutations	NULL
of	NULL
L1	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
,	NULL
L2	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
both	NULL
L1	NULL
and	NULL
L2	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
were	NULL
assayed	NULL
in	NULL
either	NULL
the	NULL
presence	NULL
of	NULL
wild-type	NULL
adenovirus	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
or	NULL
dl	NULL
434	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
either	NULL
HeLa	NULL
(	NULL
A	NULL
)	NULL
or	NULL
HUT	NULL
78	NULL
(	NULL
B	NULL
)	NULL
and	NULL
CAT	NULL
assays	NULL
performed	NULL
at	NULL
36	NULL
h	NULL
post-transfection	NULL
.	NULL

Table	NULL
I.	NULL
Gene	NULL
expression	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
in	NULL
HeLa	NULL
and	NULL
HUT	NULL
78	NULL
cells	NULL
constructs	NULL
CAT	NULL
conversion	NULL
(	NULL
%	NULL
)	NULL
(	NULL
+	NULL
)	NULL
ELA/E1B	NULL
(	NULL
-	NULL
)	NULL
E1A/E1B	NULL
HeLa	NULL
cells	NULL
wild-type	NULL
32.6	NULL
+	NULL
8.2	NULL
1.3	NULL
+04	NULL
L1	NULL
12.8	NULL
£	NULL
4.0	NULL
0.52	NULL
+	NULL
0.1	NULL
L2	NULL
18.4	NULL
£	NULL
3.8	NULL
0.52	NULL
+	NULL
0.1	NULL
L1/L2	NULL
14.6	NULL
#	NULL
2.6	NULL
0.41	NULL
+	NULL
0.03	NULL
HUT	NULL
78	NULL
cells	NULL
wild-type	NULL
34.6	NULL
+	NULL
#	NULL
9.5	NULL
16.0	NULL
£54	NULL
L1	NULL
44.7	NULL
+	NULL
10.8	NULL
25.8	NULL
+	NULL
8.9	NULL
L2	NULL
0.94	NULL
+	NULL
0.4	NULL
0.32	NULL
+	NULL
0.2	NULL
L1/L2	NULL
3.0	NULL
#	NULL
0.9	NULL
1.0	NULL
#	NULL
0.6	NULL
CAT	NULL
conversion	NULL
was	NULL
determined	NULL
by	NULL
scintillation	NULL
counting	NULL
of	NULL
acetylated	NULL
and	NULL
unacetylated	NULL
[	NULL
'*Cchloramphenicol	NULL
for	NULL
E3	NULL
CAT	NULL
constructs	NULL
transfected	NULL
into	NULL
HeLa	NULL
or	NULL
HUT	NULL
78	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
wild-type	NULL
adenovirus	NULL
[	NULL
(	NULL
+	NULL
)	NULL
E1A/E1B	NULL
]	NULL
or	NULL
di	NULL
434	NULL
[	NULL
(	NULL
-	NULL
)	NULL
E1A/E1B	NULL
]	NULL
.	NULL

Values	NULL
and	NULL
standard	NULL
deviations	NULL
were	NULL
calculated	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

transfection	NULL
and	NULL
CAT	NULL
activity	NULL
determined	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
E3	NULL
CAT	NULL
constructs	NULL
was	NULL
strongly	NULL
induced	NULL
by	NULL
the	NULL
ElA/E1B	NULL
proteins	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
Figure	NULL
4A	NULL
,	NULL
lanes	NULL
1-4	NULL
)	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
L1	NULL
,	NULL
L2	NULL
or	NULL
L1/L2	NULL
domains	NULL
(	NULL
Figure	NULL
4A	NULL
,	NULL
lanes	NULL
2-4	NULL
)	NULL
resulted	NULL
in	NULL
~2-fold	NULL
decreases	NULL
in	NULL
gene	NULL
expression	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
construct	NULL
(	NULL
Figure	NULL
4A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Table	NULL
I	NULL
shows	NULL
quantitation	NULL
of	NULL
CAT	NULL
assays	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
on	NULL
HeLa	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
binding	NULL
domains	NULL
have	NULL
minimal	NULL
effects	NULL
on	NULL
E3	NULL
gene	NULL
expression	NULL
on	NULL
HeLa	NULL
cells	NULL
consistent	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
HeLa	NULL
cellular	NULL
proteins	NULL
were	NULL
not	NULL
detected	NULL
binding	NULL
to	NULL
these	NULL
motifs	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
E1A/E1B	NULL
was	NULL
capable	NULL
of	NULL
activating	NULL
the	NULL
E3	NULL
promoter	NULL
to	NULL
high	NULL
levels	NULL
in	NULL
lymphocytes	NULL
,	NULL
we	NULL
first	NULL
tested	NULL
whether	NULL
adenovirus	NULL
could	NULL
infect	NULL
lymphocytes	NULL
and	NULL
produce	NULL
high	NULL
levels	NULL
of	NULL
ElA	NULL
mRNA	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
harvested	NULL
Fig	NULL
5	NULL
.	NULL

RNase	NULL
protection	NULL
of	NULL
ElA	NULL
mRNA	NULL
.	NULL

Either	NULL
wild-type	NULL
adenovirus	NULL
or	NULL
dl	NULL
434	NULL
at	NULL
an	NULL
m.o.i	NULL
.	NULL

of	NULL
20	NULL
was	NULL
used	NULL
to	NULL
infect	NULL
HeLa	NULL
or	NULL
HUT	NULL
78	NULL
cells	NULL
and	NULL
cytoplasmic	NULL
RNA	NULL
was	NULL
harvested	NULL
at	NULL
36	NULL
h.	NULL
RNase	NULL
protection	NULL
with	NULL
an	NULL
internally	NULL
labeled	NULL
265	NULL
bp	NULL
probe	NULL
derived	NULL
from	NULL
a	NULL
Smal-Xba	NULL
ElA	NULL
fragment	NULL
cloned	NULL
into	NULL
pGEM	NULL
3	NULL
was	NULL
used	NULL
.	NULL

Lane	NULL
1	NULL
contains	NULL
probe	NULL
along	NULL
,	NULL
lane	NULL
2	NULL
contains	NULL
probe	NULL
and	NULL
T2	NULL
ribonuclease	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
contain	NULL
HeLa	NULL
RNA	NULL
from	NULL
infection	NULL
with	NULL
either	NULL
dl	NULL
434	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
wild-type	NULL
adenovirus	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
contain	NULL
HUT	NULL
78	NULL
RNA	NULL
from	NULL
infection	NULL
with	NULL
either	NULL
dl	NULL
434	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
or	NULL
wild-type	NULL
adenovirus	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
265	NULL
bp	NULL
ElA	NULL
probe	NULL
and	NULL
the	NULL
220	NULL
ElA	NULL
mRNA	NULL
protected	NULL
species	NULL
are	NULL
indicated	NULL
.	NULL

at	NULL
36	NULL
h	NULL
post-infection	NULL
from	NULL
HUT	NULL
78	NULL
cells	NULL
infected	NULL
with	NULL
either	NULL
wild-type	NULL
or	NULL
dl	NULL
434	NULL
virus	NULL
and	NULL
RNase	NULL
protection	NULL
analysis	NULL
performed	NULL
with	NULL
an	NULL
E1A	NULL
specific	NULL
probe	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
also	NULL
infected	NULL
with	NULL
these	NULL
viruses	NULL
and	NULL
cytoplasmic	NULL
RNA	NULL
harvested	NULL
for	NULL
RNase	NULL
protection	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
5	NULL
,	NULL
high	NULL
levels	NULL
of	NULL
ElA	NULL
138	NULL
mRNA	NULL
was	NULL
found	NULL
in	NULL
both	NULL
HeLa	NULL
and	NULL
HUT	NULL
78	NULL
cells	NULL
infected	NULL
with	NULL
wild-type	NULL
adenovirus	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
,	NULL
but	NULL
not	NULL
dl	NULL
434	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
220	NULL
bp	NULL
generated	NULL
ElA	NULL
specific	NULL
species	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
lymphocytes	NULL
can	NULL
be	NULL
infected	NULL
with	NULL
adenovirus	NULL
and	NULL
produce	NULL
high	NULL
levels	NULL
of	NULL
ElA	NULL
mRNA	NULL
after	NULL
infection	NULL
.	NULL

Electroporation	NULL
of	NULL
either	NULL
the	NULL
E3	NULL
wild-type	NULL
,	NULL
L1	NULL
,	NULL
L2	NULL
or	NULL
L1/L2	NULL
constructs	NULL
into	NULL
virus	NULL
infected	NULL
HUT	NULL
78	NULL
cells	NULL
was	NULL
then	NULL
performed	NULL
and	NULL
CAT	NULL
activity	NULL
determined	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
4B	NULL
,	NULL
the	NULL
wild-type	NULL
E3	NULL
construct	NULL
gave	NULL
high	NULL
levels	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
E1A/E1B	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
L2	NULL
domain	NULL
(	NULL
Figure	NULL
4B	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
which	NULL
contains	NULL
a	NULL
consensus	NULL
NF-x	NULL
B	NULL
binding	NULL
sequence	NULL
resulted	NULL
in	NULL
severe	NULL
decreases	NULL
in	NULL
gene	NULL
expression	NULL
while	NULL
mutations	NULL
of	NULL
the	NULL
L1	NULL
domain	NULL
(	NULL
Figure	NULL
4B	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
which	NULL
diverges	NULL
from	NULL
the	NULL
consensus	NULL
NF-x	NULL
B	NULL
binding	NULL
sequence	NULL
resulted	NULL
in	NULL
minimal	NULL
effects	NULL
on	NULL
E3	NULL
gene	NULL
expression	NULL
.	NULL

Combining	NULL
mutations	NULL
of	NULL
both	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
(	NULL
Figure	NULL
4B	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
slight	NULL
but	NULL
reproducible	NULL
increase	NULL
in	NULL
gene	NULL
expression	NULL
over	NULL
that	NULL
of	NULL
the	NULL
L2	NULL
mutation	NULL
alone	NULL
.	NULL

These	NULL
constructs	NULL
yielded	NULL
the	NULL
same	NULL
pattern	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
E1A/E1B	NULL
proteins	NULL
except	NULL
that	NULL
gene	NULL
expression	NULL
of	NULL
each	NULL
construct	NULL
was	NULL
induced	NULL
~2-fold	NULL
(	NULL
Figure	NULL
4B	NULL
,	NULL
lanes	NULL
1-4	NULL
)	NULL
.	NULL

Quantitation	NULL
of	NULL
these	NULL
CAT	NULL
assays	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
I.	NULL
L2	NULL
regulation	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
is	NULL
independent	NULL
of	NULL
positional	NULL
effects	NULL
We	NULL
also	NULL
wished	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
position	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
were	NULL
critical	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
6A	NULL
,	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
were	NULL
synthesized	NULL
that	NULL
reversed	NULL
the	NULL
positions	NULL
of	NULL
these	NULL
domains	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
.	NULL

The	NULL
wild-type	NULL
construct	NULL
designated	NULL
WT	NULL
'	NULL
contains	NULL
the	NULL
L2	NULL
sequence	NULL
in	NULL
the	NULL
position	NULL
of	NULL
Lymphoid	NULL
Domain	NULL
1	NULL
and	NULL
the	NULL
L1	NULL
sequence	NULL
in	NULL
the	NULL
position	NULL
of	NULL
Lymphoid	NULL
Domain	NULL
2	NULL
.	NULL

Construct	NULL
L1	NULL
'	NULL
mutates	NULL
the	NULL
L2	NULL
sequences	NULL
in	NULL
Lymphoid	NULL
Domain	NULL
1	NULL
,	NULL
construct	NULL
L2	NULL
'	NULL
mutates	NULL
the	NULL
L1	NULL
sequence	NULL
in	NULL
Lymphoid	NULL
Domain	NULL
2	NULL
and	NULL
construct	NULL
L12	NULL
'	NULL
mutates	NULL
both	NULL
L1	NULL
Adenovirus	NULL
early	NULL
region	NULL
3	NULL
promoter	NULL
and	NULL
L2	NULL
sequences	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
constructs	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
wild-type	NULL
E3	NULL
promoter	NULL
was	NULL
fused	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
and	NULL
introduced	NULL
into	NULL
both	NULL
HeLa	NULL
and	NULL
HUT	NULL
78	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
electroporation	NULL
studies	NULL
into	NULL
HUT	NULL
78	NULL
cells	NULL
shown	NULL
in	NULL
Figure	NULL
6B	NULL
,	NULL
expression	NULL
from	NULL
the	NULL
WT	NULL
'	NULL
construct	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
parental	NULL
E3	NULL
construct	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
L2	NULL
sequences	NULL
in	NULL
Lymphoid	NULL
Domain	NULL
(	NULL
L1	NULL
'	NULL
)	NULL
resulted	NULL
in	NULL
marked	NULL
decreases	NULL
in	NULL
E3	NULL
gene	NULL
expression	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
while	NULL
mutation	NULL
of	NULL
the	NULL
L1	NULL
sequences	NULL
in	NULL
Lymphoid	NULL
Domain	NULL
2	NULL
(	NULL
L2	NULL
'	NULL
)	NULL
resulted	NULL
in	NULL
minimal	NULL
changes	NULL
in	NULL
E3	NULL
gene	NULL
expression	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
both	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
sequences	NULL
(	NULL
L12	NULL
'	NULL
)	NULL
resulted	NULL
in	NULL
severe	NULL
decreases	NULL
in	NULL
E3	NULL
gene	NULL
expression	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
several	NULL
other	NULL
experiments	NULL
there	NULL
was	NULL
a	NULL
2-	NULL
to	NULL
3-fold	NULL
increase	NULL
of	NULL
E3	NULL
gene	NULL
expression	NULL
with	NULL
the	NULL
L12	NULL
'	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
L1	NULL
'	NULL
construct	NULL
,	NULL
again	NULL
indicating	NULL
a	NULL
potential	NULL
negative	NULL
regulatory	NULL
role	NULL
for	NULL
the	NULL
L1	NULL
domain	NULL
.	NULL

All	NULL
constructs	NULL
exhibited	NULL
low	NULL
expression	NULL
in	NULL
uninfected	NULL
HeLa	NULL
cells	NULL
but	NULL
their	NULL
expression	NULL
was	NULL
markedly	NULL
induced	NULL
in	NULL
adenovirus	NULL
infected	NULL
HeLa	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
significant	NULL
position	NULL
independent	NULL
role	NULL
for	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
sequences	NULL
in	NULL
regulating	NULL
E3	NULL
gene	NULL
expression	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Discussion	NULL
Adenovirus	NULL
infection	NULL
of	NULL
lymphocytes	NULL
is	NULL
a	NULL
primary	NULL
site	NULL
of	NULL
viral	NULL
infection	NULL
in	NULL
humans	NULL
.	NULL

The	NULL
adenovirus	NULL
genome	NULL
and	NULL
its	NULL
gene	NULL
products	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
Horvath	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Horvath	NULL
and	NULL
Weber	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
these	NULL
adenovirus	NULL
infected	NULL
lymphocytes	NULL
escape	NULL
host	NULL
immunologic	NULL
destruction	NULL
are	NULL
unknown	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
gene	NULL
expression	NULL
of	NULL
the	NULL
early	NULL
region	NULL
3	NULL
promoter	NULL
in	NULL
both	NULL
HeLa	NULL
cells	NULL
and	NULL
the	NULL
lymphoid	NULL
cell	NULL
line	NULL
HUT	NULL
78	NULL
.	NULL

E3	NULL
expression	NULL
in	NULL
lymphoid	NULL
cells	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
two	NULL
NF-x	NULL
B	NULL
motifs	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
.	NULL

Both	NULL
of	NULL
these	NULL
sites	NULL
served	NULL
as	NULL
binding	NULL
sites	NULL
for	NULL
cellular	NULL
factors	NULL
found	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
lymphoid	NULL
,	NULL
but	NULL
not	NULL
HeLa	NULL
extracts	NULL
.	NULL

These	NULL
motifs	NULL
were	NULL
not	NULL
critical	NULL
for	NULL
expression	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

E1A	NULL
induction	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
was	NULL
minimal	NULL
in	NULL
lymphocytes	NULL
as	NULL
compared	NULL
with	NULL
HeLa	NULL
cells	NULL
,	NULL
although	NULL
the	NULL
same	NULL
overall	NULL
expression	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
was	NULL
seen	NULL
in	NULL
wild-type	NULL
adenovirus	NULL
infected	NULL
HeLa	NULL
cells	NULL
and	NULL
lymphocytes	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
the	NULL
NF-x	NULL
B	NULL
motifs	NULL
diminish	NULL
the	NULL
need	NULL
for	NULL
ElA	NULL
to	NULL
maintain	NULL
high	NULL
levels	NULL
of	NULL
E3	NULL
gene	NULL
expression	NULL
.	NULL

What	NULL
role	NULL
does	NULL
this	NULL
high	NULL
level	NULL
of	NULL
E3	NULL
promoter	NULL
gene	NULL
expression	NULL
in	NULL
lymphocytes	NULL
have	NULL
on	NULL
the	NULL
biology	NULL
of	NULL
adenovirus	NULL
infec-tion	NULL
?	NULL

The	NULL
E3	NULL
gene	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
encode	NULL
a	NULL
19	NULL
kd	NULL
glycoprotein	NULL
which	NULL
is	NULL
capable	NULL
of	NULL
complexing	NULL
with	NULL
class	NULL
I	NULL
MHC	NULL
antigens	NULL
(	NULL
Kvist	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
;	NULL
Persson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
,	NULL
1980	NULL
;	NULL
Signas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
;	NULL
Kampe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
;	NULL
Andersson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Burgert	NULL
and	NULL
Kvist	NULL
,	NULL
1985	NULL
;	NULL
Paabo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Burgert	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
expression	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
cells	NULL
is	NULL
associated	NULL
with	NULL
ability	NULL
of	NULL
cells	NULL
to	NULL
escape	NULL
immunologic	NULL
surveillance	NULL
.	NULL

Adenovirus	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
infect	NULL
lymphocytes	NULL
without	NULL
establishing	NULL
a	NULL
lytic	NULL
infection	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
high	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
19	NULL
kd	NULL
glycoprotein	NULL
may	NULL
help	NULL
to	NULL
maintain	NULL
viral	NULL
persistence	NULL
in	NULL
lymphocytes	NULL
(	NULL
Persson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
,	NULL
1989	NULL
;	NULL
Signas	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

Differences	NULL
in	NULL
the	NULL
primary	NULL
sequence	NULL
of	NULL
the	NULL
NF-x	NULL
B	NULL
motifs	NULL
may	NULL
alter	NULL
the	NULL
ability	NULL
of	NULL
these	NULL
factors	NULL
to	NULL
modulate	NULL
gene	NULL
expression	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
L2	NULL
motif	NULL
which	NULL
contained	NULL
a	NULL
concensus	NULL
NF-x	NULL
B	NULL
binding	NULL
motif	NULL
resulted	NULL
in	NULL
severe	NULL
decreases	NULL
in	NULL
E3	NULL
4439	NULL
J.L.Williams	NULL
et	NULL
af	NULL
.	NULL

A	NULL
L12	NULL
AGTCG	NULL
ACCTCGAGCGA	NULL
AC	NULL
'	NULL
Al	NULL
Fig	NULL
6	NULL
.	NULL

Reversal	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Sequences	NULL
from	NULL
-165	NULL
to	NULL
-108	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
.	NULL

The	NULL
wild-type	NULL
E3	NULL
promoter	NULL
(	NULL
WT	NULL
)	NULL
and	NULL
reversal	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
(	NULL
WT	NULL
'	NULL
)	NULL
are	NULL
indicated	NULL
,	NULL
as	NULL
are	NULL
mutations	NULL
(	NULL
L1	NULL
'	NULL
,	NULL
L2	NULL
'	NULL
,	NULL
L12	NULL
'	NULL
)	NULL
of	NULL
these	NULL
domains	NULL
.	NULL

The	NULL
underlined	NULL
nucleotides	NULL
indicate	NULL
changes	NULL
in	NULL
the	NULL
sequence	NULL
relative	NULL
to	NULL
the	NULL
wild-type	NULL
promoter	NULL
.	NULL

The	NULL
regions	NULL
corresponding	NULL
to	NULL
the	NULL
lymphoid-specific	NULL
elements	NULL
are	NULL
offset	NULL
to	NULL
allow	NULL
comparison	NULL
of	NULL
the	NULL
transversed	NULL
sequences	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
wild-type	NULL
E3	NULL
promoter	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
the	NULL
inverted	NULL
L1/L2	NULL
domains	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
(	NULL
WT	NULL
)	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
or	NULL
this	NULL
latter	NULL
promoter	NULL
containing	NULL
mutations	NULL
of	NULL
the	NULL
L2	NULL
sequences	NULL
(	NULL
L1	NULL
'	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
L1	NULL
sequences	NULL
(	NULL
L2	NULL
'	NULL
)	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
or	NULL
L1	NULL
and	NULL
L2	NULL
sequences	NULL
(	NULL
L12	NULL
'	NULL
)	NULL
were	NULL
electroporated	NULL
into	NULL
HUT	NULL
78	NULL
cells	NULL
and	NULL
CAT	NULL
assays	NULL
performed	NULL
at	NULL
30	NULL
h	NULL
post-electroporation	NULL
.	NULL

gene	NULL
expression	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

This	NULL
motif	NULL
had	NULL
a	NULL
higher	NULL
binding	NULL
affinity	NULL
than	NULL
the	NULL
L1	NULL
motif	NULL
.	NULL

This	NULL
latter	NULL
site	NULL
contained	NULL
7	NULL
out	NULL
of	NULL
10	NULL
bp	NULL
homology	NULL
with	NULL
the	NULL
NF-x	NULL
B	NULL
motif	NULL
.	NULL

However	NULL
,	NULL
mutations	NULL
of	NULL
this	NULL
site	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
resulted	NULL
in	NULL
a	NULL
slight	NULL
,	NULL
but	NULL
reproducible	NULL
,	NULL
increase	NULL
in	NULL
E3	NULL
gene	NULL
expression	NULL
when	NULL
coupled	NULL
to	NULL
the	NULL
L2	NULL
mutation	NULL
suggesting	NULL
a	NULL
potential	NULL
negative	NULL
regulatory	NULL
role	NULL
.	NULL

Reversal	NULL
of	NULL
these	NULL
motifs	NULL
in	NULL
the	NULL
E3	NULL
promoter	NULL
indicated	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
sequences	NULL
on	NULL
regulating	NULL
E3	NULL
gene	NULL
expression	NULL
was	NULL
dependent	NULL
on	NULL
their	NULL
primary	NULL
sequence	NULL
rather	NULL
than	NULL
their	NULL
position	NULL
.	NULL

It	NULL
is	NULL
also	NULL
important	NULL
to	NULL
note	NULL
an	NULL
additional	NULL
constraint	NULL
on	NULL
the	NULL
E3	NULL
promoter	NULL
,	NULL
in	NULL
that	NULL
it	NULL
is	NULL
contained	NULL
within	NULL
the	NULL
coding	NULL
region	NULL
the	NULL
adenovirus	NULL
100	NULL
kd	NULL
late	NULL
protein	NULL
(	NULL
Lewis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
limitations	NULL
may	NULL
exist	NULL
on	NULL
the	NULL
primary	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
E3	NULL
regulatory	NULL
elements	NULL
due	NULL
to	NULL
restrictions	NULL
imposed	NULL
by	NULL
conservation	NULL
of	NULL
the	NULL
amino	NULL
acid	NULL
composition	NULL
of	NULL
this	NULL
late	NULL
protein	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
NF-x	NULL
B	NULL
motifs	NULL
to	NULL
modulate	NULL
viral	NULL
gene	NULL
expression	NULL
has	NULL
been	NULL
reported	NULL
with	NULL
other	NULL
viral	NULL
promoters	NULL
including	NULL
SV40	NULL
(	NULL
Davidson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Nomiyama	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Ondek	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Schirm	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Macchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
cytomegalovirus	NULL
(	NULL
Boshart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
,	NULL
and	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
Nabel	NULL
and	NULL
Baltimore	NULL
,	NULL
1987	NULL
;	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988a	NULL
,	NULL
b	NULL
;	NULL
Gaynor	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

A	NULL
single	NULL
NF-x	NULL
B	NULL
motif	NULL
from	NULL
the	NULL
SV40	NULL
promoter	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
little	NULL
effect	NULL
on	NULL
heterologous	NULL
promoter	NULL
activation	NULL
(	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Macchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

However	NULL
,	NULL
multimerizing	NULL
these	NULL
motifs	NULL
resulted	NULL
in	NULL
enhancer	NULL
function	NULL
in	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
cells	NULL
(	NULL
Nomiyama	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Ondek	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Schirm	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Macchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
proteins	NULL
present	NULL
in	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
cells	NULL
including	NULL
EBP1	NULL
(	NULL
Clark	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988b	NULL
)	NULL
,	NULL
H2TFl	NULL
(	NULL
Baldwin	NULL
and	NULL
Sharp	NULL
,	NULL
1987	NULL
,	NULL
1988	NULL
)	NULL
,	NULL
and	NULL
KBF1	NULL
(	NULL
Yano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
,	NULL
can	NULL
bind	NULL
to	NULL
these	NULL
motifs	NULL
and	NULL
activate	NULL
gene	NULL
expression	NULL
.	NULL

This	NULL
was	NULL
confirmed	NULL
by	NULL
gel	NULL
retardation	NULL
and	NULL
methylation	NULL
interference	NULL
analysis	NULL
indicating	NULL
that	NULL
both	NULL
H2TF1	NULL
and	NULL
NF-x	NULL
B	NULL
,	NULL
which	NULL
bound	NULL
to	NULL
the	NULL
SV40	NULL
x	NULL
B	NULL
motif	NULL
,	NULL
were	NULL
present	NULL
in	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
lymphoid	NULL
and	NULL
non-lymphoid	NULL
cells	NULL
(	NULL
Macchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
with	NULL
the	NULL
E3	NULL
promoter	NULL
and	NULL
previous	NULL
results	NULL
with	NULL
the	NULL
immunoglobulin	NULL
x	NULL
enhancer	NULL
suggest	NULL
that	NULL
NF-x	NULL
B	NULL
binding	NULL
is	NULL
restricted	NULL
to	NULL
lymphoid	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
substances	NULL
such	NULL
as	NULL
phorbol	NULL
esters	NULL
(	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986a	NULL
,	NULL
b	NULL
;	NULL
Atchison	NULL
and	NULL
Perry	NULL
,	NULL
1987	NULL
;	NULL
Lenardo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Nelson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Pierce	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Wirth	NULL
and	NULL
Baltimore	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

However	NULL
,	NULL
using	NULL
oligonucleotides	NULL
from	NULL
the	NULL
HIV	NULL
enhancer	NULL
which	NULL
contains	NULL
two	NULL
NF-x	NULL
B	NULL
motifs	NULL
,	NULL
we	NULL
have	NULL
detected	NULL
binding	NULL
to	NULL
these	NULL
motifs	NULL
with	NULL
HeLa	NULL
extract	NULL
by	NULL
gel	NULL
retardation	NULL
and	NULL
DNase	NULL
I	NULL
footprinting	NULL
(	NULL
Wu	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1988a	NULL
;	NULL
Gaynor	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

These	NULL
4440	NULL
results	NULL
suggest	NULL
that	NULL
cellular	NULL
factors	NULL
from	NULL
HeLa	NULL
cells	NULL
are	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
x	NULL
B	NULL
motifs	NULL
,	NULL
but	NULL
this	NULL
binding	NULL
may	NULL
also	NULL
depend	NULL
on	NULL
the	NULL
nucleotide	NULL
sequence	NULL
of	NULL
regions	NULL
flanking	NULL
the	NULL
NF-x	NULL
B	NULL
motif	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
the	NULL
mutation	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
domains	NULL
did	NULL
result	NULL
in	NULL
small	NULL
but	NULL
reproducible	NULL
decreases	NULL
in	NULL
E3	NULL
gene	NULL
expression	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
factors	NULL
present	NULL
in	NULL
HeLa	NULL
cells	NULL
can	NULL
likely	NULL
interact	NULL
with	NULL
these	NULL
binding	NULL
domains	NULL
.	NULL

However	NULL
,	NULL
we	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
detect	NULL
binding	NULL
to	NULL
these	NULL
motifs	NULL
with	NULL
HeLa	NULL
extract	NULL
even	NULL
in	NULL
concentrations	NULL
5-to	NULL
10-fold	NULL
higher	NULL
than	NULL
with	NULL
lymphoid	NULL
extracts	NULL
.	NULL

Domains	NULL
other	NULL
than	NULL
NF-x	NULL
B	NULL
have	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
important	NULL
in	NULL
E3	NULL
gene	NULL
expression	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Kornuc	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Both	NULL
CREB	NULL
and	NULL
API	NULL
binding	NULL
sites	NULL
were	NULL
found	NULL
to	NULL
be	NULL
important	NULL
for	NULL
gene	NULL
expression	NULL
on	NULL
HeLa	NULL
cells	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Kornuc	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

These	NULL
sites	NULL
were	NULL
also	NULL
critical	NULL
for	NULL
gene	NULL
expression	NULL
in	NULL
HUT78	NULL
cells	NULL
.	NULL

E1A	NULL
was	NULL
critical	NULL
for	NULL
activation	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
in	NULL
HeLa	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
lymphoid	NULL
specific	NULL
regions	NULL
may	NULL
lessen	NULL
the	NULL
requirement	NULL
for	NULL
ElA	NULL
to	NULL
obtain	NULL
high	NULL
levels	NULL
of	NULL
E3	NULL
gene	NULL
expression	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
role	NULL
for	NULL
these	NULL
lymphoid	NULL
specific	NULL
domains	NULL
in	NULL
the	NULL
maintenance	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
E3	NULL
gene	NULL
expression	NULL
.	NULL

Such	NULL
expression	NULL
may	NULL
be	NULL
one	NULL
determinant	NULL
of	NULL
the	NULL
maintenance	NULL
of	NULL
adenoviral	NULL
persistence	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cells	NULL
and	NULL
virus	NULL
stocks	NULL
Wild-type	NULL
Ad5	NULL
was	NULL
grown	NULL
in	NULL
HeLa	NULL
suspension	NULL
cultures	NULL
maintained	NULL
in	NULL
MEM	NULL
+	NULL
5	NULL
%	NULL
newborn	NULL
calf	NULL
serum	NULL
,	NULL
and	NULL
titers	NULL
were	NULL
determined	NULL
by	NULL
plaque	NULL
formation	NULL
on	NULL
293	NULL
cells	NULL
(	NULL
Graham	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
)	NULL
.	NULL

AdS	NULL
di	NULL
434	NULL
(	NULL
Grodzicker	NULL
and	NULL
Klessig	NULL
,	NULL
1980	NULL
)	NULL
was	NULL
grown	NULL
on	NULL
monolayers	NULL
of	NULL
the	NULL
complementing	NULL
293	NULL
cell	NULL
line	NULL
and	NULL
titers	NULL
were	NULL
determined	NULL
by	NULL
plaque	NULL
assay	NULL
on	NULL
this	NULL
cell	NULL
line	NULL
.	NULL

HeLa	NULL
monolayers	NULL
were	NULL
maintained	NULL
in	NULL
Iscovers	NULL
media	NULL
with	NULL
5	NULL
%	NULL
newborn	NULL
calf	NULL
serum	NULL
containing	NULL
penicillin	NULL
and	NULL
streptomycin	NULL
.	NULL

HUT	NULL
78	NULL
cells	NULL
(	NULL
Gootenberg	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
,	NULL
H9	NULL
(	NULL
Popovic	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
,	NULL
Jurkat	NULL
(	NULL
Gillis	NULL
and	NULL
Watson	NULL
,	NULL
1981	NULL
)	NULL
,	NULL
and	NULL
Raji	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
Iscoves	NULL
media	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
at	NULL
a	NULL
density	NULL
of	NULL
10°-10°	NULL
cells/ml	NULL
.	NULL

Transfections	NULL
and	NULL
CAT	NULL
assays	NULL
HeLa	NULL
plates	NULL
were	NULL
split	NULL
on	NULL
the	NULL
day	NULL
prior	NULL
to	NULL
transfection	NULL
so	NULL
that	NULL
each	NULL
100	NULL
mm	NULL
plate	NULL
was	NULL
50-70	NULL
%	NULL
confluent	NULL
at	NULL
the	NULL
time	NULL
of	NULL
transfection	NULL
.	NULL

Cells	NULL
were	NULL
infected	NULL
with	NULL
either	NULL
wild-type	NULL
adenovirus	NULL
or	NULL
dl	NULL
434	NULL
at	NULL
an	NULL
m.0.i	NULL
.	NULL

of	NULL
20	NULL
.	NULL

At	NULL
1	NULL
h	NULL
post-infection	NULL
,	NULL
fresh	NULL
media	NULL
with	NULL
cytosine	NULL
arabinoside	NULL
(	NULL
ara-C	NULL
)	NULL
(	NULL
20	NULL
ug/ml	NULL
)	NULL
was	NULL
added	NULL
.	NULL

At	NULL
4	NULL
h	NULL
post-infection	NULL
,	NULL
media	NULL
was	NULL
removed	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
each	NULL
E3	NULL
CAT	NULL
construct	NULL
was	NULL
transfected	NULL
onto	NULL
identically	NULL
prepared	NULL
plates	NULL
.	NULL

Fresh	NULL
media	NULL
containing	NULL
ara-C	NULL
was	NULL
added	NULL
,	NULL
the	NULL
media	NULL
changed	NULL
12	NULL
h	NULL
later	NULL
and	NULL
the	NULL
plates	NULL
harvested	NULL
at	NULL
32	NULL
h	NULL
post-transfections	NULL
for	NULL
CAT	NULL
analysis	NULL
as	NULL
described	NULL
(	NULL
Gorman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

Plasmids	NULL
An	NULL
EcoRI-Sacl	NULL
(	NULL
-236	NULL
to	NULL
+31	NULL
)	NULL
fragment	NULL
containing	NULL
the	NULL
E3	NULL
promoter	NULL
was	NULL
cloned	NULL
into	NULL
Smal/Sacl	NULL
mpl8	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Oligonucleotides	NULL
complementary	NULL
to	NULL
regions	NULL
L1	NULL
and	NULL
L2	NULL
containing	NULL
specified	NULL
point	NULL
mutations	NULL
were	NULL
synthesized	NULL
(	NULL
courtesy	NULL
of	NULL
T.Sutherland	NULL
,	NULL
Molecular	NULL
Biology	NULL
Institute	NULL
and	NULL
Jonsson	NULL
Cancer	NULL
Centre	NULL
)	NULL
and	NULL
used	NULL
for	NULL
oligonucleotide-directed	NULL
mutagenesis	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Each	NULL
mutant	NULL
was	NULL
verified	NULL
by	NULL
dideoxy	NULL
sequencing	NULL
.	NULL

The	NULL
RF	NULL
DNA	NULL
from	NULL
each	NULL
isolate	NULL
was	NULL
prepared	NULL
,	NULL
the	NULL
E3	NULL
upstream	NULL
region	NULL
was	NULL
isolated	NULL
and	NULL
cloned	NULL
into	NULL
a	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
(	NULL
RSV	NULL
)	NULL
CAT	NULL
derivative	NULL
.	NULL

The	NULL
fragments	NULL
were	NULL
also	NULL
cloned	NULL
into	NULL
pUCI19	NULL
for	NULL
use	NULL
in	NULL
DNase	NULL
I	NULL
footprinting	NULL
(	NULL
Galas	NULL
and	NULL
Schmitz	NULL
,	NULL
1978	NULL
)	NULL
.	NULL

Plasmid	NULL
constructions	NULL
An	NULL
EcoRI-Sacl	NULL
(	NULL
-236	NULL
to	NULL
+31	NULL
)	NULL
fragment	NULL
from	NULL
the	NULL
E3	NULL
promoter	NULL
was	NULL
cloned	NULL
into	NULL
mp	NULL
18	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Oligonucleotides	NULL
complementary	NULL
to	NULL
regions	NULL
L1	NULL
or	NULL
L2	NULL
containing	NULL
the	NULL
indicated	NULL
point	NULL
mutations	NULL
were	NULL
synthesized	NULL
(	NULL
courtesy	NULL
of	NULL
T.Sutherland	NULL
,	NULL
MBI	NULL
and	NULL
Jonsson	NULL
Cancer	NULL
Center	NULL
)	NULL
and	NULL
used	NULL
for	NULL
oligonucleotide-directed	NULL
mutagenesis	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommended	NULL
protocol	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

All	NULL
mutations	NULL
were	NULL
verified	NULL
by	NULL
dideoxy-sequencing	NULL
.	NULL

A	NULL
BamHI-Sacl	NULL
fragment	NULL
was	NULL
prepared	NULL
from	NULL
the	NULL
RF	NULL
DNA	NULL
of	NULL
each	NULL
mutant	NULL
and	NULL
ligated	NULL
into	NULL
BamHI-Sacl	NULL
pJGFCAT19	NULL
,	NULL
a	NULL
derivative	NULL
of	NULL
RSV	NULL
CAT	NULL
,	NULL
for	NULL
transfection	NULL
analysis	NULL
and	NULL
into	NULL
pUC19	NULL
for	NULL
DNase	NULL
I	NULL
protection	NULL
studies	NULL
.	NULL

For	NULL
construction	NULL
of	NULL
the	NULL
lymphoid	NULL
domain	NULL
transversion	NULL
plasmids	NULL
WT	NULL
``	NULL
,	NULL
L1	NULL
'	NULL
,	NULL
L2	NULL
'	NULL
and	NULL
L12	NULL
'	NULL
,	NULL
site-directed	NULL
mutagenesis	NULL
was	NULL
used	NULL
to	NULL
introduce	NULL
an	NULL
Neo	NULL
!	NULL

site	NULL
at	NULL
position	NULL
-108	NULL
of	NULL
the	NULL
E3	NULL
-236/+31	NULL
fragment	NULL
from	NULL
a	NULL
mutation	NULL
,	NULL
MIV	NULL
,	NULL
used	NULL
in	NULL
an	NULL
earlier	NULL
study	NULL
(	NULL
Kornuc	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
which	NULL
contains	NULL
a	NULL
Psfl	NULL
site	NULL
in	NULL
the	NULL
MIV	NULL
mutation	NULL
at	NULL
position	NULL
-165	NULL
.	NULL

A	NULL
Psil-Sacl	NULL
fragment	NULL
from	NULL
the	NULL
RF	NULL
DNA	NULL
of	NULL
the	NULL
MIV/Nco	NULL
!	NULL

I*	NULL
mutant	NULL
construct	NULL
was	NULL
isolated	NULL
and	NULL
cloned	NULL
into	NULL
pUC19	NULL
.	NULL

This	NULL
plasmid	NULL
served	NULL
as	NULL
a	NULL
shuttle	NULL
vector	NULL
for	NULL
construction	NULL
of	NULL
the	NULL
transversion	NULL
plasmids	NULL
.	NULL

To	NULL
construct	NULL
the	NULL
transversion	NULL
plasmids	NULL
,	NULL
complementary	NULL
oligonucleotides	NULL
for	NULL
each	NULL
of	NULL
the	NULL
constructs	NULL
were	NULL
synthesized	NULL
with	NULL
Ps	NULL
and	NULL
Ncol	NULL
overhangs	NULL
,	NULL
annealed	NULL
and	NULL
ligated	NULL
into	NULL
a	NULL
Pstl/Nco	NULL
!	NULL

shuttle	NULL
vector	NULL
.	NULL

Verification	NULL
of	NULL
the	NULL
plasmids	NULL
was	NULL
performed	NULL
by	NULL
dideoxy	NULL
sequencing	NULL
.	NULL

Pstl-Sacl	NULL
fragments	NULL
from	NULL
each	NULL
of	NULL
the	NULL
transversion	NULL
constructs	NULL
,	NULL
the	NULL
shuttle	NULL
vector	NULL
and	NULL
the	NULL
parent	NULL
MIV	NULL
plasmid	NULL
were	NULL
ligated	NULL
into	NULL
Psil/Sacl	NULL
pJGFCAT19	NULL
for	NULL
use	NULL
in	NULL
transfection	NULL
analysis	NULL
.	NULL

ANase	NULL
protection	NULL
Cytoplasmic	NULL
RNA	NULL
was	NULL
prepared	NULL
from	NULL
either	NULL
HeLa	NULL
or	NULL
HUT	NULL
78	NULL
cells	NULL
(	NULL
108	NULL
cells	NULL
)	NULL
at	NULL
36	NULL
h	NULL
post-infection	NULL
with	NULL
either	NULL
dl	NULL
434	NULL
or	NULL
Ad5	NULL
at	NULL
an	NULL
m.0.1	NULL
.	NULL

of	NULL
20	NULL
as	NULL
described	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

A	NULL
Smal-Xbal	NULL
from	NULL
an	NULL
AdS	NULL
ElA	NULL
138	NULL
cDNA	NULL
was	NULL
cloned	NULL
into	NULL
pGEM	NULL
3	NULL
,	NULL
linearized	NULL
with	NULL
EcoRI	NULL
and	NULL
SP6	NULL
polymerase	NULL
and	NULL
-UTP	NULL
was	NULL
used	NULL
to	NULL
generate	NULL
a	NULL
265	NULL
bp	NULL
internally	NULL
labeled	NULL
RNA	NULL
probe	NULL
for	NULL
use	NULL
in	NULL
an	NULL
RNase	NULL
protection	NULL
assay	NULL
.	NULL

Protected	NULL
bands	NULL
of	NULL
220	NULL
bp	NULL
indicated	NULL
the	NULL
13	NULL
$	NULL
form	NULL
of	NULL
ELA	NULL
produced	NULL
in	NULL
wild-type	NULL
adenovirus	NULL
infected	NULL
cells	NULL
.	NULL

Electroporation	NULL
HUT	NULL
78	NULL
cells	NULL
(	NULL
3	NULL
x	NULL
10	NULL
%	NULL
cells	NULL
)	NULL
were	NULL
infected	NULL
with	NULL
either	NULL
wild-type	NULL
AdS	NULL
or	NULL
dl	NULL
434	NULL
at	NULL
an	NULL
m.0.i	NULL
.	NULL

of	NULL
20	NULL
for	NULL
1	NULL
h	NULL
in	NULL
3	NULL
ml	NULL
media	NULL
and	NULL
then	NULL
diluted	NULL
to	NULL
30	NULL
ml	NULL
.	NULL

After	NULL
4	NULL
h	NULL
of	NULL
the	NULL
infection	NULL
,	NULL
cells	NULL
were	NULL
spun	NULL
at	NULL
IK	NULL
for	NULL
5	NULL
min	NULL
and	NULL
washed	NULL
with	NULL
5	NULL
ml	NULL
of	NULL
serum-free	NULL
Iscoves	NULL
media	NULL
.	NULL

Cells	NULL
were	NULL
resuspended	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
8	NULL
%	NULL
10	NULL
``	NULL
cells/ml	NULL
in	NULL
electroporation	NULL
media	NULL
(	NULL
Iscoves	NULL
media	NULL
and	NULL
20	NULL
%	NULL
FCS	NULL
)	NULL
.	NULL

2	NULL
x	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
DNA	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
cell/DNA	NULL
mixture	NULL
was	NULL
then	NULL
electroporated	NULL
at	NULL
1180	NULL
a	NULL
Farads	NULL
and	NULL
250	NULL
volts	NULL
using	NULL
a	NULL
BRL	NULL
electroporator	NULL
.	NULL

Cells	NULL
were	NULL
suspended	NULL
at	NULL
3	NULL
x	NULL
10°	NULL
cells/ml	NULL
and	NULL
harvested	NULL
at	NULL
30	NULL
h	NULL
post-electroporation	NULL
.	NULL

The	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
ara-C	NULL
to	NULL
block	NULL
viral	NULL
replication	NULL
did	NULL
not	NULL
alter	NULL
E3	NULL
gene	NULL
expression	NULL
on	NULL
HUT	NULL
78	NULL
cells	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
HeLa	NULL
,	NULL
HUT	NULL
78	NULL
,	NULL
Jurkat	NULL
,	NULL
H9	NULL
or	NULL
Raji	NULL
nuclear	NULL
extract	NULL
(	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
was	NULL
loaded	NULL
onto	NULL
a	NULL
heparin-agarose	NULL
column	NULL
,	NULL
and	NULL
eluted	NULL
with	NULL
buffer	NULL
containing	NULL
0.4	NULL
M	NULL
KCI	NULL
.	NULL

The	NULL
extract	NULL
was	NULL
dialyzed	NULL
into	NULL
20	NULL
mM	NULL
Tris	NULL
pH	NULL
7.9-100	NULL
mM	NULL
KCI-O0.2	NULL
mM	NULL
DTT-O0.2	NULL
mM	NULL
PMSF	NULL
and	NULL
used	NULL
in	NULL
DNase	NULL
I	NULL
footprinting	NULL
assays	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
studies	NULL
were	NULL
done	NULL
with	NULL
a	NULL
clone	NULL
containing	NULL
the	NULL
E3	NULL
upstream	NULL
region	NULL
(	NULL
-236/	NULL
+31	NULL
)	NULL
either	NULL
wild-type	NULL
or	NULL
containing	NULL
L1	NULL
,	NULL
L2	NULL
or	NULL
L1/L2	NULL
mutations	NULL
cloned	NULL
into	NULL
Smal/Sacl	NULL
pUC19	NULL
.	NULL

The	NULL
coding	NULL
strand	NULL
was	NULL
labeled	NULL
with	NULL
T4	NULL
kinase	NULL
and	NULL
[	NULL
y-°P	NULL
]	NULL
JATP	NULL
at	NULL
the	NULL
HindIII	NULL
site	NULL
in	NULL
the	NULL
polylinker	NULL
and	NULL
a	NULL
400	NULL
bp	NULL
fragment	NULL
was	NULL
isolated	NULL
by	NULL
electroelution	NULL
after	NULL
cutting	NULL
with	NULL
Pvull	NULL
.	NULL

Fragments	NULL
for	NULL
footprinting	NULL
each	NULL
of	NULL
the	NULL
point	NULL
mutants	NULL
were	NULL
labeled	NULL
and	NULL
isolated	NULL
in	NULL
the	NULL
same	NULL
manner	NULL
.	NULL

From	NULL
1	NULL
to	NULL
5	NULL
ng	NULL
of	NULL
end-labeled	NULL
probe	NULL
was	NULL
added	NULL
to	NULL
each	NULL
50	NULL
gl	NULL
reaction	NULL
mix	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
HeLa	NULL
extract	NULL
,	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
3	NULL
ug	NULL
)	NULL
,	NULL
and	NULL
final	NULL
concentrations	NULL
of	NULL
10	NULL
mM	NULL
Tris	NULL
pH	NULL
7.6	NULL
,	NULL
50	NULL
mM	NULL
KCl	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
and	NULL
58	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol	NULL
.	NULL

The	NULL
DNA	NULL
and	NULL
extract	NULL
were	NULL
allowed	NULL
to	NULL
bind	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
the	NULL
reaction	NULL
volume	NULL
was	NULL
increased	NULL
to	NULL
100	NULL
gl	NULL
,	NULL
and	NULL
final	NULL
concentrations	NULL
of	NULL
DNase	NULL
I	NULL
(	NULL
0.4-3.0	NULL
ug/ml	NULL
)	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
;	NULL
and	NULL
2.5	NULL
mM	NULL
CaCl	NULL
,	NULL
were	NULL
added	NULL
.	NULL

The	NULL
reac-	NULL
Adenovirus	NULL
early	NULL
region	NULL
3	NULL
promoter	NULL
tion	NULL
was	NULL
stopped	NULL
after	NULL
30	NULL
s	NULL
with	NULL
phenol	NULL
-chloroform	NULL
,	NULL
ethanol	NULL
precipitated	NULL
,	NULL
and	NULL
loaded	NULL
onto	NULL
a	NULL
10	NULL
%	NULL
polyacrylamide-8	NULL
M	NULL
urea	NULL
sequencing	NULL
gel	NULL
.	NULL

All	NULL
gels	NULL
were	NULL
then	NULL
subjected	NULL
to	NULL
autoradiography	NULL
.	NULL

Gel	NULL
retardations	NULL
HeLa	NULL
or	NULL
HUT	NULL
78	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
in	NULL
gel	NULL
retardations	NULL
with	NULL
oligonucleotides	NULL
complementary	NULL
to	NULL
the	NULL
NFI	NULL
,	NULL
L1	NULL
and	NULL
L2	NULL
sites	NULL
.	NULL

Double	NULL
stranded	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
NFl	NULL
(	NULL
5-TAGTTGG	NULL
CCCGCTGCCCTGGTGTA-3	NULL
)	NULL
,	NULL
L1	NULL
(	NULL
5-CGCACCACTGTGGTACTT	NULL
CCCAGAGAGACG-3	NULL
'	NULL
)	NULL
and	NULL
L2	NULL
(	NULL
5-GGGTACCAGGAAAGTCCCG	NULL
CTCCCGCTCCC-3	NULL
'	NULL
)	NULL
binding	NULL
sites	NULL
of	NULL
the	NULL
E3	NULL
promoter	NULL
were	NULL
purified	NULL
and	NULL
labeled	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
20	NULL
000	NULL
c.p.m	NULL
.	NULL

(	NULL
~1	NULL
ng	NULL
)	NULL
used	NULL
in	NULL
gel	NULL
retardations	NULL
with	NULL
3	NULL
ug	NULL
of	NULL
either	NULL
HUT	NULL
78	NULL
or	NULL
HeLa	NULL
nuclear	NULL
extract	NULL
as	NULL
described	NULL
(	NULL
Komuc	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Oligonucleotide	NULL
competitions	NULL
were	NULL
performed	NULL
with	NULL
either	NULL
a	NULL
2	NULL
,	NULL
6	NULL
,	NULL
15	NULL
or	NULL
30-fold	NULL
molar	NULL
excess	NULL
of	NULL
either	NULL
L1	NULL
,	NULL
L2	NULL
or	NULL
NFI	NULL
oligonucleotides	NULL
.	NULL

Acknowledgements	NULL
We	NULL
thank	NULL
Charles	NULL
Leavitt	NULL
for	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
Grant	NULL
CA30981	NULL
and	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Veteran	NULL
's	NULL
Administration	NULL
.	NULL

R.G	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
a	NULL
Faculty	NULL
Research	NULL
Award	NULL
from	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
,	NULL
J.G	NULL
.	NULL

from	NULL
the	NULL
UCLA	NULL
Medical	NULL
Scientist	NULL
Training	NULL
Program	NULL
and	NULL
J.W	NULL
.	NULL

from	NULL
USDHA	NULL
GM	NULL
07104-15	NULL
.	NULL

References	NULL
Andersson	NULL
,	NULL
M.	NULL
,	NULL
Paabo	NULL
,	NULL
S.	NULL
,	NULL
Nilsson	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Peterson	NULL
,	NULL
P	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Cell	NULL
,	NULL
43	NULL
,	NULL
215-222	NULL
.	NULL

Atchison	NULL
,	NULL
M.L	NULL
.	NULL

and	NULL
Perry	NULL
,	NULL
R.P	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
,	NULL
48	NULL
,	NULL
121-128	NULL
.	NULL

Baldwin	NULL
,	NULL
A.S.	NULL
and	NULL
Sharp	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
7	NULL
,	NULL
305-313	NULL
.	NULL

Baldwin	NULL
,	NULL
A.S.	NULL
and	NULL
Sharp	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
723-727	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Bohnlein	NULL
,	NULL
E	NULL
.	NULL

,	NULL
Lowenthal	NULL
,	NULL
J	NULL
.	NULL

W.	NULL
,	NULL
Wano	NULL
,	NULL
Y.	NULL
,	NULL
Franza	NULL
,	NULL
B.R	NULL
.	NULL

and	NULL
Greene	NULL
.	NULL

W.C.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
,	NULL
241	NULL
,	NULL
1652-1655	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988a	NULL
)	NULL
Cell	NULL
,	NULL
53	NULL
,	NULL
211-217	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988b	NULL
)	NULL
Science	NULL
,	NULL
242	NULL
,	NULL
540-546	NULL
.	NULL

Berk	NULL
,	NULL
A.J	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
20	NULL
,	NULL
45-79	NULL
.	NULL

Berk	NULL
,	NULL
A.J	NULL
.	NULL

,	NULL
Lee	NULL
,	NULL
F.	NULL
,	NULL
Harrison	NULL
,	NULL
T.	NULL
,	NULL
Williams	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Sharp	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Cell	NULL
,	NULL
17	NULL
,	NULL
935-944	NULL
.	NULL

Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
Lowenthal	NULL
,	NULL
J	NULL
.	NULL

W.	NULL
,	NULL
Sickewitz	NULL
,	NULL
M.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Franza	NULL
,	NULL
B.R	NULL
.	NULL

and	NULL
Greene	NULL
,	NULL
W.C.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
,	NULL
53	NULL
,	NULL
827-836	NULL
.	NULL

Boshart.M	NULL
.	NULL

,	NULL
Weber	NULL
,	NULL
F.	NULL
,	NULL
Jahn	NULL
,	NULL
G.	NULL
,	NULL
Dorsch-Hasler	NULL
,	NULL
K.	NULL
,	NULL
Fleckenstein	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
Cell	NULL
,	NULL
41	NULL
,	NULL
521-530	NULL
.	NULL

Burgert	NULL
,	NULL
H.G	NULL
.	NULL

and	NULL
Kvist	NULL
,	NULL
S	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Cell	NULL
,	NULL
41	NULL
,	NULL
987-997	NULL
.	NULL

Burgert	NULL
,	NULL
H.G	NULL
.	NULL

,	NULL
Maryanski	NULL
,	NULL
J.L	NULL
.	NULL

and	NULL
Kvist	NULL
,	NULL
S	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
1356-1360	NULL
.	NULL

Clark	NULL
,	NULL
L.	NULL
,	NULL
Nicholson	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Hay	NULL
,	NULL
R.T	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
2	NULL
,	NULL
991-1002	NULL
.	NULL

Cross	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
Halden	NULL
,	NULL
N.F	NULL
.	NULL

,	NULL
Lenardo	NULL
,	NULL
M.J.	NULL
and	NULL
Leonard	NULL
,	NULL
W.J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
244	NULL
,	NULL
466-469	NULL
.	NULL

Davidson	NULL
,	NULL
I.	NULL
,	NULL
Fromental	NULL
,	NULL
C.	NULL
,	NULL
Augereau	NULL
,	NULL
P.	NULL
,	NULL
Wildeman	NULL
,	NULL
A.	NULL
,	NULL
Zenke	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Chambon	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Nature	NULL
,	NULL
323	NULL
,	NULL
544-548	NULL
.	NULL

Dignam	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Lebovitz	NULL
,	NULL
R.M	NULL
.	NULL

and	NULL
Roeder	NULL
,	NULL
R.G	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
11	NULL
,	NULL
1475-1489	NULL
.	NULL

Galas	NULL
,	NULL
D.J	NULL
.	NULL

and	NULL
Schmitz	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
5	NULL
,	NULL
3157-3170	NULL
.	NULL

Garcia	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Wu	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Gaynor	NULL
,	NULL
R.B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
15	NULL
,	NULL
8367-8385	NULL
.	NULL

Gaynor	NULL
,	NULL
R.B	NULL
.	NULL

,	NULL
Kuwabara	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
Wu	NULL
,	NULL
F.K	NULL
.	NULL

,	NULL
Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Harrich	NULL
,	NULL
D.	NULL
,	NULL
Briskin	NULL
,	NULL
M.	NULL
,	NULL
Wall	NULL
,	NULL
R.	NULL
and	NULL
Sigman	NULL
,	NULL
D.S	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
9406-9410	NULL
.	NULL

Gillis	NULL
,	NULL
S	NULL
.	NULL

and	NULL
Watson	NULL
,	NULL
J.J	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
152	NULL
,	NULL
1709-1719	NULL
.	NULL

Gootenberg	NULL
,	NULL
J.E	NULL
.	NULL

,	NULL
Ruscetti	NULL
,	NULL
F.W	NULL
.	NULL

,	NULL
Mier	NULL
,	NULL
J.W	NULL
.	NULL

,	NULL
Gazdar	NULL
,	NULL
A.	NULL
and	NULL
Gallo	NULL
,	NULL
R.C	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
154	NULL
,	NULL
1403-1418	NULL
.	NULL

Gorman	NULL
,	NULL
C	NULL
.	NULL

M.	NULL
,	NULL
Moffat	NULL
,	NULL
and	NULL
Howard	NULL
,	NULL
B.H	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
1044-1051	NULL
.	NULL

Grahan	NULL
,	NULL
F.L	NULL
.	NULL

,	NULL
Smiley	NULL
,	NULL
J.	NULL
,	NULL
Russel	NULL
,	NULL
W.C.	NULL
and	NULL
Naim	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
J.	NULL
Gen	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
36	NULL
,	NULL
59-72	NULL
.	NULL

Grodzicker.T	NULL
.	NULL

and	NULL
Klessig	NULL
,	NULL
D.F	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
Cell	NULL
,	NULL
21	NULL
,	NULL
453-463	NULL
.	NULL

Horvath.J	NULL
.	NULL

and	NULL
Weber.J.M	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Virol	NULL
,	NULL
62	NULL
,	NULL
341-345	NULL
.	NULL

Horvath.J	NULL
.	NULL

,	NULL
Palkonyay	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Weber	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
59	NULL
,	NULL
189-192	NULL
.	NULL

Hurst	NULL
,	NULL
H.C	NULL
.	NULL

and	NULL
Jones	NULL
,	NULL
N.C	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
1	NULL
,	NULL
1132-1146	NULL
.	NULL

Jones	NULL
,	NULL
N.C	NULL
.	NULL

and	NULL
Shenk.T	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
76	NULL
,	NULL
3665-3669	NULL
.	NULL

Kampe,0.D	NULL
.	NULL

,	NULL
Beligrau	NULL
,	NULL
D..	NULL
,	NULL
Hammerling	NULL
,	NULL
U.	NULL
,	NULL
Lind	NULL
,	NULL
P.	NULL
,	NULL
Paabo	NULL
,	NULL
S.	NULL
,	NULL
Severinsson	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Peterson	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
268	NULL
,	NULL
10594-10598	NULL
.	NULL

4441	NULL
J.L	NULL
.	NULL

Williams	NULL
et	NULL
al	NULL
.	NULL

Kanno	NULL
,	NULL
M.	NULL
,	NULL
Fromental	NULL
,	NULL
C.	NULL
,	NULL
Staub	NULL
,	NULL
A.	NULL
,	NULL
Ruffenach	NULL
,	NULL
F.	NULL
,	NULL
Davidson	NULL
,	NULL
L	NULL
and	NULL
Chambon	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
4205-4214	NULL
.	NULL

Kawakami	NULL
,	NULL
K.	NULL
,	NULL
Scheidereit	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Roeder	NULL
,	NULL
R.G	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
4700-4704	NULL
.	NULL

Komuc	NULL
,	NULL
M.	NULL
,	NULL
Kliewer	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Garcia	NULL
,	NULL
J.	NULL
,	NULL
Harrich	NULL
,	NULL
D.	NULL
,	NULL
Li	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Gaynor	NULL
,	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
64	NULL
,	NULL
2004-2013	NULL
.	NULL

Kvist	NULL
,	NULL
S.	NULL
,	NULL
Ostberg	NULL
,	NULL
L.	NULL
,	NULL
Persson	NULL
,	NULL
H.	NULL
,	NULL
Phillipson	NULL
,	NULL
L.	NULL
and	NULL
Peterson	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
75	NULL
,	NULL
5674-5678	NULL
.	NULL

Lavery	NULL
,	NULL
D.	NULL
,	NULL
Fu	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
Lufkin	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Chen-Kiang	NULL
,	NULL
$	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
61	NULL
,	NULL
1466-1472	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
,	NULL
Pierce	NULL
,	NULL
J.W	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Science	NULL
,	NULL
236	NULL
,	NULL
1573-1577	NULL
.	NULL

Lewis	NULL
,	NULL
J.B.	NULL
,	NULL
Atkins	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
Anderson	NULL
,	NULL
C	NULL
.	NULL

W.	NULL
,	NULL
Baurm	NULL
,	NULL
PR	NULL
.	NULL

and	NULL
Gesteland	NULL
,	NULL
R.D	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
73	NULL
,	NULL
1344-1349	NULL
.	NULL

Macchi	NULL
,	NULL
M.	NULL
,	NULL
Bornert	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
Davidson	NULL
,	NULL
I.	NULL
,	NULL
Kanno	NULL
,	NULL
M.	NULL
,	NULL
Rosales	NULL
,	NULL
R.	NULL
,	NULL
Vigneron	NULL
,	NULL
M.	NULL
,	NULL
Xiao	NULL
,	NULL
J.H	NULL
.	NULL

,	NULL
Fromental	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Chambon	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
4115-4127	NULL
.	NULL

Nabel	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
,	NULL
326	NULL
,	NULL
711-713	NULL
.	NULL

Nelson	NULL
,	NULL
B.	NULL
,	NULL
Hellman	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Sen	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
8	NULL
,	NULL
3526-3531	NULL
.	NULL

Nomiyama	NULL
,	NULL
H.	NULL
,	NULL
Fromental	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Chambon	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
7881-7885	NULL
.	NULL

Ondek	NULL
,	NULL
B.	NULL
,	NULL
Shephard	NULL
,	NULL
A.	NULL
and	NULL
Herr	NULL
,	NULL
W.	NULL
(	NULL
1987	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
6	NULL
,	NULL
1017-1025	NULL
.	NULL

Paabo	NULL
,	NULL
S.	NULL
,	NULL
Nilsson	NULL
,	NULL
T.	NULL
and	NULL
Peterson	NULL
,	NULL
P	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
,	NULL
9665-9669	NULL
.	NULL

Persson	NULL
,	NULL
H.	NULL
,	NULL
Signas	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Philipson	NULL
,	NULL
L	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
29	NULL
,	NULL
938-948	NULL
.	NULL

Persson	NULL
,	NULL
H.	NULL
,	NULL
Jansson	NULL
,	NULL
M.	NULL
and	NULL
Philipson	NULL
,	NULL
L	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
136	NULL
,	NULL
375-394	NULL
.	NULL

Pierce	NULL
,	NULL
J	NULL
.	NULL

W.	NULL
,	NULL
Lenardo	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
1482-1486	NULL
.	NULL

Popovic.M	NULL
.	NULL

,	NULL
Read-Connole	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Gallo	NULL
,	NULL
R.C	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Lancet	NULL
,	NULL
2	NULL
,	NULL
1472-1473	NULL
.	NULL

Schirm	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Jirieny	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1987	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
1	NULL
,	NULL
224-230	NULL
.	NULL

Schreck	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Baeuerle	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
3	NULL
,	NULL
1281-1286	NULL
.	NULL

Sen	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986a	NULL
)	NULL
Cell	NULL
,	NULL
46	NULL
,	NULL
705-716	NULL
.	NULL

Sen	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1986b	NULL
)	NULL
Cell	NULL
,	NULL
47	NULL
,	NULL
921-928	NULL
.	NULL

Signas	NULL
,	NULL
C.	NULL
,	NULL
Katze	NULL
,	NULL
M.G	NULL
.	NULL

,	NULL
Persson	NULL
,	NULL
H.	NULL
and	NULL
Philipson	NULL
,	NULL
L	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Nature	NULL
,	NULL
299	NULL
,	NULL
175-178	NULL
.	NULL

Wirth	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
7	NULL
,	NULL
3109-3113	NULL
.	NULL

Wu	NULL
,	NULL
F.K	NULL
.	NULL

,	NULL
Garcia	NULL
,	NULL
J.	NULL
,	NULL
Mitsuyasu	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Gaynor	NULL
,	NULL
R.B	NULL
.	NULL

(	NULL
19882	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
62	NULL
,	NULL
218-225	NULL
.	NULL

Wu	NULL
,	NULL
F.K	NULL
.	NULL

,	NULL
Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Harrich	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Gaynor	NULL
,	NULL
R.B	NULL
.	NULL

(	NULL
1988b	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
7	NULL
,	NULL
2117-2129	NULL
.	NULL

Yano,0	NULL
.	NULL

,	NULL
Kanellopoulos	NULL
,	NULL
J.	NULL
,	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Israel	NULL
,	NULL
A.	NULL
and	NULL
Kourilsky	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
6	NULL
,	NULL
3317-3324	NULL
.	NULL

Received	NULL
on	NULL
May	NULL
15	NULL
,	NULL
1990	NULL
;	NULL
revised	NULL
on	NULL
September	NULL
15	NULL
,	NULL
1990	NULL
4442	NULL

